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Other than the provision of clean water, food and sanitation, no other 
deliberate human intervention has prolonged the human life span at par with 
the provision of vaccines and other chemotherapeutic strategies to control 
the infectious diseases. Since 1950, out of 25 vaccines that have been 
licensed in the US, 15 of these are in routine universal use. On the horizon 
are vaccines not only to prevent infectious diseases, but also offer means to 
fight against cancer and a host of other human ills. It appears that disease 
will always be a part of the human existence. Nonetheless, it is worthwhile 
to pause and consider the role and importance of vaccines on individual and 
collective public health. It is fact that vaccines represent the only drugs or 
biologic agents that are ought to be administered to every single human 
being on earth. In fact, it is estimated that no single medical intervention has 
been as effective as the widespread use of vaccines in increasing the life 
span during this century. Furthermore, vaccine research has led to 
fundamental insights in immune system of the host, which have 
subsequently led to the control, treatment or eradication of many human 
diseases including smallpox, polio, measles and other dreadful infectious 
diseases. However, despite the known benefit, safety and efficacy of 
vaccines, we fail to exploit the benefits of universal immunization on both 
national and international level. For example, the overall costs of vaccine 
preventable diseases in US adults have been estimated to exceed 10 billion 
dollars per year. As a society, we have passively deemed it acceptable to pay 
this cost, despite the existence of safe and effective vaccines, which could 
prevent the majority of these diseases at a substantially lower cost. Why? In 
part, the answer may be that we fail to understand, or believe, that it costs 
more for society to treat vaccine preventable diseases than to have prevented 
them in the first place. Such passive decisions lead to unnecessary suffering, 
premature death and the consequent long-term morbidity or disability as 
repercussion of such infections. Similarly, unless we explicitly recognize the 
limitations of the current ways in which we think about disease and its 
prevention, it is unlikely that scientific discovery and advancement in these 
areas will proceed at an acceptable pace. 
Traditional vaccines based on killed or attenuated bacteria and 
viruses have been responsible for preventing millions of deaths each year 
from infectious diseases. However, upsurge in antibiotic-resistant bacteria, 
the emergence of new pathogens and concerns over the safety of killed and 
attenuated vaccines have highlighted the requirement for new vaccines and 
also for the refinement of existing vaccines to render them safer and more 
effective. Recent advances in our understanding of immunity to infectious 
diseases and in the identification of protective antigens in the range of 
pathogens, together with developments in gene cloning ensuing expression 
of effective antigens, have enabled a more rational approach to the 
development of safer subunit vaccines, consisting of specific antigenic 
components of the pathogen. Furthermore better insight of mechanisms of 
action of adjuvants have made it possible to design antigen-adjuvant 
combinations capable of inducing desirable protective immunity against 
range of infectious diseases. New vaccines are presently under development 
and in testing for the control of infectious diseases, including human 
immunodeficiency virus (HIV) and tuberculosis. Several of these vaccines 
are composed of synthetic, recombinant, or highly purified subunit antigens. 
Subunit vaccines are designed to include only specific antigens required for 
protective immunization. These vaccines are ought to be more safer than 
whole-inactivated or live-attenuated vaccines. However, the purity of the 
subunit antigens and the absence of the self-adjuvanting immunomodulatory 
components associated with attenuated or killed vaccines often result in 
weaker immunogenicity. Immunologic adjuvants are agents that enhance 
specific immune responses to vaccines. Formulation of vaccines with potent 
adjuvants is an attractive approach for improving the performance of subunit 
antigens based vaccines. Adjuvants have diverse mechanisms of action and 
should be selected for use on the basis of the route of administration and the 
type of immune response (antibody, cell-mediated, or mucosal immunity) 
that is desired for a particular vaccine. 
Keeping into consideration the limitation associated with currently 
available vaccine that generally activate humoral immune response, while 
fail to induce cell mediated immune responses. It is need of the hour to 
develop vaccination strategies that can activate both humoral as well as 
strong CTL response simultaneously. This becomes more pertinent where 
the vaccine is meant to control intracellular pathogens. In the present study 
we have developed novel fusogenic liposomes made up of lipids isolated 
from membrane of E. coli (Escheriosomes), which have been reported to 
possess strong fusogenic potential. Escheriosome based vaccine can activate 
both humoral and cell mediated immune response simultaneously. 
In the first part of the study we have developed novel fusogenic 
liposomes made up of lipids from E. coli (Escheriosomes). These liposomes 
have been shown to undergo membrane membrane fusion with cytoplasmic 
membrane of target cell including professional antigen presenting cells. The 
study demonstrates that antigen encapsulated in escheriosomes could be 
successfully delivered simultaneously to the cytosolic as well as cndosomal 
processing pathways of antigen presenting cells, leading to the generation of 
both CD4* T-helper and CDS"^  cytotoxic T cell response. In contrast, 
encapsulation of same antigen in egg PC liposomes, just like Antigen-
Incomplete Freund's Adjuvant (IFA) complex, has inefficient access to the 
cytosolic pathway of MHC I dependent antigen presentation and failed to 
generate antigen specific CDS"^  cytotoxic T cell response. However, both egg 
PC liposomes as well as escheriosomes encapsulated antigen elicited strong 
humoral immune response in immunized animals but antibody titre was 
significantly higher in the group of animals immunized with escheriosomes 
encapsulated antigen. Furthermore, antigen entrapped in cschcrio.somes 
stimulates antigen specific CD4'^  T cell proliferation and also enhances the 
level of IL-2, IFN-y and IL-4 in the immunized animals. These results imply 
usage of liposome based adjuvant as potential candidate vaccine capable of 
eliciting both cell mediated as well as humoral immune responses. 
Besides antibody generation, the vaccination strategy used for 
protection against intracellular pathogen should be capable of generating 
specific cytotoxic T lymphocytes (CTL) response as well. Like other 
intracellular pathogens, effective immunization against Salmonella infection 
also needs activation of both humoral as well as cell-mediated immune 
response in unison. In the next part of the study escheriosomes based 
vaccines were evaluated for generating protective immunity against 
Salmonella typhimurium infection in murine model. Immunization of 
BALB/c mice with escheriosome encapsulated Salmonella typhimurium 
cytosolic antigens resulted in higher antigen specific cytotoxic T cell 
lymphocyte as well as IgG responses. In contrast, animals immunized with 
free or egg-PC liposome encapsulated antigen failed to induce antigen 
specific CDS"^  CTLs. Further, immunization with escheriosome-encapsulated 
antigen resulted in significant enhancement in the release of IFN-y and 
IgG2a in the experimental animals. Interestingly, the immunization with 
escheriosome-encapsulated antigen resulted in upregulation of CD80 and 
CD86 on the surface of antigen presenting cells (APCs) as well. Finally, the 
results of the present study reveal that immunization of animals with 
escheriosomes encapsulated antigen protected them against virulent S. 
typhimurium infection as revealed by increased survival, and reduced 
bacterial burden in vital organs of the immunized animals. The data of the 
present study suggest that escheriosomes can emerge as an effective vehicle 
for intracellular delivery of antigen and thus hold promise in development of 
liposome based vaccine against salmonella and other intracellular infections. 
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1. Vaccines and Vaccination 
Dcvclopmcnl of vaccines constitutes the greatest achievement in the 
field of modern medical sciences. It is perhaps one of the most cost elTective 
and economic therapeutic intervention available today. Conventional 
vaccines consisted of live attenuated pathogens, whole inactivated 
organisms, or inactivated toxins. Although such forms of vaccine have 
proved successful in the past, several drawbacks have limited their use 
against more challenging diseases such as hepatitis C and AIDS etc. First, 
certain live-attenuated vaccines can cause disease in immunosuppressed 
individuals by reverting to a more virulent phenotype. Second, whole 
inactivated vaccines (e.g., Bordetella pertussis) contain reactogenic 
components that can cause undesirable side effects. Third, some pathogens 
are difficult or even impossible to grow in culture (e.g., hepatitis B, hepatitis 
C, and human papilloma virus etc.), making preparation of a vaccine 
problematic. During recent past, several approaches in vaccine development 
have emerged that may have significant advantages over traditional 
approaches. These new strategies include recombinant protein subunits, 
synthetic peptides, and plasmid DNA. Although they offer advantages such 
as reduced toxicity, they are poorly immunogenic when administered alone. 
This is particularly true for vaccines based on recombinant proteins or 
peptides. Further, traditional vaccines are heterogeneous and contain many 
epitopes, some of which can provide additional T-cell help or function as 
adjuvants (e.g., bacterial DNA in whole-cell vaccines). Therefore, a great 
need exists for immunological adjuvants that are potent, safe, and 
compatible with new-generation vaccines, including DNA vaccines. 
Vaccines can be broadly classified into four major groups: - live, 
killed or inactivated, subunit and genetic (Table 1). Each of these groups is 
further divisible into multiple categories, which include recombinant-
derived antigens as well as native microorganisms and their components. In 
i^iewetaop^CUiBt'cUiM^ 
addition, there are new enabling technologies such as delivery systems and 
vectors, which can be exploited to achieve coveted goals. Most disease 
targets, whether infectious or noninfectious in origin, can be approached by 
the application of several different vaccine technologies, as can be tested 
during the discovery phase of research. 
Table 1 
Comparative properties of active vaccines 
Type of vaccine 
Live vaccines 
Subunit vaccines 
(killed inactivated) 
Genetic vaccines 
(DNA-based) 
Salient features 
* Able to replicate in the 
host 
*Attenuated in 
pathogenicity 
* Unable to replicate in 
the host 
* Stimulate synthesis of 
antigens only upon 
administration in the cells 
Advantages 
I.May elicit broader immune 
responses 
2.May require fewer doses 
3.Generally longer lasting 
protection 
1.Cannot multiply or revert 
to pathogenicity 
2.Generally less reactogenic 
3.Non transmissible to 
another person 
4. Usually more feasible 
technically 
l.EIicil cellular immune 
responses 
2. Standardized method of 
production 
1.1 Live vaccines 
Conventional live viral and bacterial vaccines are produced by 
selecting avirulent mutants, which can establish themselves in host, however 
fail to invoke full blown disease. The mutations are generally induced by 
treatment of the organism with mutagens, chemicals, heat or passage in 
vitro. Following these mutational events, avirulent mutants are selected and 
tested in vivo. In most cases, multiple mutations induced, led to the 
development of attenuated form of pathogen although it is often unknown 
what constellations of genes are altered to achieve attenuation. Using this 
approach, it is difficult to modulate the degree of attenuation and if the 
attenuation happens to be due to a single-point mutation, there is a high 
probability of reversion to virulence when organism is administered to the 
host. A well-known example of such reversion was observed in case of oral 
polio vaccines when virus gets virulent upon administration (Minor et. 
a/. 1986). This reversion can result to full blown disease, especially to the 
underlying immunosuppressive conditions. Secondly, the vaccinee sheds 
virulent virus into the environment, which can infect non-vaccinated 
contacts. 
Nevertheless, some live vaccines come very close to meeting the 
criteria for an ideal vaccine of being able to elicit life long protection with 
minimal reactogenicity. Such vaccines consist of microorganisms (usually 
viruses) that replicate similarly to the natural microorganism in vivo, thereby 
eliciting an immune response similar to that of natural infection. The live 
vaccine is attenuated by technical or biological manipulations for 
eliminating its disease causing capacity. The live vaccine should be neither 
over attenuated, such that it no longer replicates sufficiently to function as a 
vaccine, nor under attenuated, whereby it retains even limited pathogenicity 
or ability to revert to pathogenicity. 
1.2 Subunit Vaccines 
Subunit vaccines are defined as those containing one or more pure or 
semi-pure antigens. In order to develop subunit vaccines it is critical to 
identify the individual components, out of a myriad of proteins and 
glycoproteins of the pathogen, that are involved in inducing protection. 
Indeed, some of the proteins present in pathogens are immunosuppressive, 
whereas immune responses to certain other proteins may actually enhance 
disease. Thus, it is crucial to identify antigenic proteins that are important 
for inducing protection and elimination of the pathogens. The potential 
advantages associated with subunit vaccines are the increased safety, less 
antigenic competition, since only a few components are included in the 
vaccine, ability to target the vaccine to the site where immunity is required 
and the ability to differentiate vaccinated from infected animals. Although 
subunit vaccines can be produced by conventional technologies, the 
purification is generally not economic due to the low quantities of protective 
antigens produced by most of the infectious agent. For example, Pasteurella 
haemolytica produces low level of extracellular toxin (leukotoxin), which is 
involved in pathogenesis and tissue, damage in the lungs of cattle (Lo et. 
a/. 1987, Shewen & Wilkins, 1982). This makes the development of 
neutralizing antibodies a very costly affair. In addition, some bacterial 
proteins required for scavenging nutrients such as iron are not expressed at 
sufficient levels to allow purification of the protective component. By 
identifying the proteins involved in inducing protective immunity and 
identifying the gene coding for these proteins it is possible to use 
recombinant DNA technology or synthetic peptide technology to produce 
sufficient quantities of these protective epitopes for incorporation into 
vaccines. 
In addition to identifying potential targets of pathogens, it is also 
possible to develop subunit vaccines, which reduce vector transmission of 
some pathogens by immunization against the vector. For example, many 
infectious agents are transmitted by blood feeding vectors. Studies have 
shown that immunization of animals against antigens present in the gut of 
the vector results in the disruption of their intestinal cell function when 
exposed to blood meal rich in antibodies directed against these intestinal 
antigens. Relying on the recombinant DNA technology to express protective 
antigen and its use in development of pathogen specific vaccine is demand 
of the ordeal. The identification and subsequent expression of such antigen 
is likely to shorten the time required to develop subunit vaccines for a large 
number of pathogens. 
The immune response to a foreign entity is determined by previous 
exposure to the same or a related structure, the dose and route of 
introduction, its biochemical composition and physical structure, and the 
immune status and genetics of the host. With the exception of host genetics 
and health, the above determinants are all amenable to manipulation and 
"targeting' with subunit vaccines. In particular, the use of adjuvants with 
subunit vaccines is an active and extremely promising area of investigation. 
Adjuvants can be used not only to augment the strength as well as duration 
of response but also to influence the type of antigen specific cell mediated 
and humoral immune responses. 
1.3 Genetic Vaccines 
A recent novel approach has been the use of DNA that encodes 
specific protective antigen. The in vitro paradigm for this approach lay in 
the transformation of mammalian cells in culture with a plasmid that directs 
the expression of a vaccine antigen from cells that take up the plasmid DNA. 
Subsequent to its uptake the administered DNA encodes antigen(s) that can 
be secreted or be associated with the cell surface in a way that would trigger 
a humoral or cellular immune response. The uptake of DNA can be 
facilitated by chemical formulation or delivery by a virus or bacteria. 
Several strategies have been exploited for immunization with genetic 
vaccine. 
1.3.1 Purified DNA 
In the early nineties, intramuscular administration of solution of 
uncoated or 'naked' DNA encoding a vaccine antigen was found to induce 
desirable immune response (Wolf et. al 1990). Cells take up the DNA, 
transcribe its expression cassette and synthesize the antigen, which may be 
processed in a similar way to that of administration of DNA subsequent to 
viral attack. Both humoral and cellular immune responses to the encoded 
antigen are elicited. The advantages of using DNA based vaccine involve 
relatively technically easy way of preparation and the ability to direct the 
synthesis of multiple copies of mRNA, that eventually results in 
amplification of both antigen synthesis and immune response. Such vaccines 
have been shown to be effective in many animal models. DNA vaccines are 
particularly proficient at eliciting cellular immune responses. Nevertheless, 
clinical efficacy for such vaccines remains to be shown. One strategy has 
been the presentation of DNA on gold microprojectiles that are 'shot' 
directly into cells, that eventually results in expression of antigen to 
stimulate an immune response (Williams et.al. 1991). DNA also has been 
coated with cationic lipids, lipospermines or other molecules, which 
neutralize its charge, while surplus cationic lipid moieties facilitate cellular 
uptake (Remye/. a/. 1994). 
1.3.2 Virus mediated delivery 
For delivery of DNA by fowlpox or canarypox virus, the expression 
cassette for the recombinant protein is integrated into the viral genome. 
Although able to infect avian species to produce disease, these poxviruses 
can infect mammalian (human) cells without inflicting any infection; hence 
can be considered as a genetic vaccine approach (Kent et a/. 1994). This 
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single round of self-limiting infection may be sufficient to elicit broad 
immunity against pathogen whose recombinant polypeptide is expressed by 
these avian poxviruses in infected cells. The approach has some basic 
advantages over vaccinia virus as these viruses have considerably less 
reactogenicity mostly because of their inability to spread within host. 
1.3.3 Bacterial delivery 
The intracellular bacteria can be engineered to deliver piasmid DNA 
into the host cells for the expression of recombinant proteins. S. flexneri has 
been attenuated by making a deletion mutant in the essential asd gene 
(Sizemore et. al. 1996). The attenuated strain can be propagated in vitro in 
the presence of diaminopimelic acid (DAP) and retains its potential to 
invade cells (as long as it maintains a piasmid encoding invasion-associated 
polypeptides). However, it cannot replicate in vivo because of the absence of 
DAP. A piasmid harboring a eukaryotic promoter and recombinant gene can 
be transformed into this strain. The resultant recombinant S. flexneri strain 
was shown to be able to invade mammalian cells in vitro and to express the 
plasmid-encoded protein as a potential vaccine antigen. Since S. flexneri 
replicates in the intestine and stimulates mucosal immunity, the vector upon 
oral administration can effectively deliver DNA to the cells to evoke 
mucosal immunity. 
1.4 Combination Vaccines 
In this strategy, combination of more than one vaccine can be 
administered to the subjects. There are two general categories of 
combination vaccines. 
1.4.1 Multidisease combination vaccines include individual 
vaccines for- several diseases. A multi disease combination is 
usually developed after each individual vaccine in the combination 
11 
'^levieiO'O^^LUei'aliM^ 
has been developed and licensed separately, so that this becomes a 
combination of licensed components. 
1.4.2 Multivalent combination vaccines are directed against more 
than one type (serotypes or serogroups) of viral or bacterial 
pathogen. A multivalent combination is developed as such from 
the outset rather than developing and licensing each individual 
serotype vaccine separately. While multivalent combinations 
invariably are mixed during the manufacturing process, 
multidisease combinations may be mixed at one of the three 
stages: (i) during the manufacturing process such that the 
combination is filled into vials or syringes? (ii) at the time of 
administration by prior mixing of different vaccines in a vial then 
using the mixture for injection or (iii) mixing of individual 
vaccine preparation at the time of administration using dual-
chambered syringe. While the first alternative is clearly preferred 
for ease of use, it is not always possible in cases where the 
combination is not compatible giving rise to fully unstable 
preparation. 
Till date three types of vaccines, two of which have been developed into 
combinations are available. Live attenuated vaccines consist of viruses or 
bacteria, which have been cultivated in vitro in a way which attenuates, i.e., 
reduces, their infectivity and pathogenicity. Such strains of viruses or 
bacteria are able to infect and replicate in vivo to some limited extent but do 
not cause disease. The second type of combination vaccine is referred to as 
non live (inactivated, killed or subunit). Such vaccines may be chemically 
inactivated viruses or bacteria (inactivated or killed), individual antigens 
purified from viruses or bacteria or expressed by recombinant host cells 
(subunit), or synthetic components such as peptides (subunit). Vaccines may 
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be combinations of live or nonlive components, but there are not yet any 
examples of successful combination of live and nonlive components 
together. The third type of vaccine has been catagorised as genetic or DNA-
based, however as this type of vaccines have entered clinical trials in recent 
past only, there are not yet examples of combinations of such vaccines. 
There are six combination vaccines, both multidisease and multivalent, 
which have been available for periods of 2 to 6 decades for routine 
immunization as discussed below. Some of these have been mixed with other 
vaccines and further developed into combination vaccines. 
1.4.1.1 DTP (Diphtheria-Tetanus-Pertussis) Vaccine 
This multi-disease non-live combination vaccine is available for over 
50 last years and required as pediatric vaccine in most major countries 
worldwide. It is typically being given three to four times in the first two 
years of life with subsequent boosters. (Ramon 1923, Plotkin& Cadoz 1997). 
1.4.2.1 Influenza Vaccine 
This trivalent inactivated combination vaccine has been available for 
over last 40 years (Kilbourne 1994). It is widely used, especially in older 
adults, for the prevention of acute disease through annual immunization. The 
vaccine consists of two HA antigen serotypes of influenza virus; one of 
serogroup A and one of serogroup B. 
1.4.2.2 Polio Vaccine 
This multivalent combination vaccine has been available in two 
different forms. The inactivated vaccine [IPV; Salk vaccine] is a 
combination of the three serotypes of poliovirus, each of which is purified 
and inactivated prior to mixing. The vaccine is indicated for immunzation 
upto four times in first two years of life (Salk & Gori, 1960). The live 
attenuated oral polio vaccine [OPV; Sabin vaccine] is trivalent, consisting of 
a combination of the three serotype viruses, each of which has been 
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attenuated through in vitro passage (Sabin 1957). The vaccine is indicated 
for immunization three to four times in the first two years of life, or is given 
in a mixed regimen w i^th the first two doses as IPV and the next two doses as 
OPV (Plotkin e/. al. 1968). 
1.4.1.2 MMR (measles, mumps, rubella) Vaccine 
This multidisease live combination vaccine has been available for 
more than 30 years (Weibel et. al, 1980). Each of the 3 components of the 
vaccines was attenuated through in vitro passage and developed as an 
individual vaccine prior to the combination being made and developed. In 
areas where the trivalent vaccine has been widely utilized, there has been a 
>99% reduction in the incidence of each of the three diseases (Paunio et. al. 
1991). 
1.4.1.3 Pneumococcal Vaccine 
This multivalent subunit vaccine has been available for over last two 
decades (Austrian et. al. 1989). Even though there are >80 known serotypes of 
Streptococcus pneumoniae (Pn), it was recognized that only limited population 
is responsible for most cases of the disease in susceptible adults as well as 
children. A 23-valent vaccine is available that has the largest number of 
separate components of any available combination vaccine currently in use or 
developed. It is indicated for immunization of older individuals. 
1.4.1.4 Meningococcal Vaccine 
This multivalent subunit vaccine has been available for more than two 
decades. Among the multiple serotypes of Neisseria meningitidis, five 
serotypes were recognized as responsible for infliction of disease in children 
and adults. The serotype specificity is carried on the Polysaccharides (Ps). 
Of the 5 Ps, type B Ps is nonimmunogenic. Therefore, the vaccine was 
developed as a mixture of 4 capsular Ps (types A, C, W-135, Y) for the 
immunization of children and adults (Armand et. al. 1982). 
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1.5 Marker Vaccine 
A marker vaccine can be either a subunit or a gene- deleted vaccine 
and is defined as one which can be used in conjunction with a diagnostic test 
to differentiate a vaccinated animal versus a carrier animal. These vaccines 
are gaining popularity in veterinary medicine where eradication of specific 
diseases is of national interest. The technology for developing marker 
vaccines has been used most extensively for eradication of herpes-viruses in 
pigs and cattle. The basis for marker vaccines is that the animals develop 
immune responses to the antigens that are present in the vaccine but not to 
antigens of the pathogen origin that have been excluded from the vaccine.. 
Since these vaccines reduce shedding from latently infected animals, it is 
possible to immunize a herd for a number of years and eventually reduce the 
shedding to such a level that only the older animals are latently infected 
(Bosch et. al. 1998). One important criterion for choosing a marker protein 
is that it must be one that induces a rapid and long-lived antibody response 
in infected animals but not in vaccinated animals even after repeated 
immunization. 
2. Immunological Adjuvants 
Immunological adjuvants were originally described by Ramon as 
"substances used in combination with a specific antigen that produce more 
immunity than the antigen alone"(Ramon 1924). This broad definition 
encompasses a very wide range of materials that can adjuvenate immune 
system of the host upon their administration (Vogel and Powell 1995). 
However, despite extensive evaluation over many years, the only adjuvants 
currently approved by the US Food & Drug Administration (Rockville, MD) 
are aluminum-based mineral salts [generically called alum](Gupta 1998). 
The most important issue in adjuvant development is safety, which has 
restricted the development of newer adjuvants (Eldman 1997). Many 
experimental adjuvants have advanced to clinical trials and some have 
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demonstrated high potency, but most have proved too toxic for routine 
clinical use. For standard prophylactic immunization in healthy individuals, 
the adjuvants that induce minimal side effect is likely to be acceptable. In 
contrast, for adjuvants that are designed to be used in life-threatening 
situations (e.g., cancer), the acceptable level of adverse events is likely to be 
higher. Additional issues that are important for adjuvant development 
include biodegradability, stability, ease of manufacture, cost, and 
applicability to a wide range of vaccines. Ideally, for ease of administration 
and patient compliance, an adjuvant should allows a vaccine to be given by a 
mucosal route. Examples of adjuvants that have been evaluated in clinical 
trials are enlisted in Table 2. Although the mechanisms of action of most of 
the adjuvants are often poorly understood, they can be broadly classified on 
the basis of their principal mode of action. However, these classifications 
become more arbitrary as immunostimulatory adjuvants are included in 
combination of vaccine delivery systems and adjuvants are combined in 
single formulations. 
2.1 Mineral salts 
The mineral salts, which have been used as adjuvants, include 
aluminium hydroxide/phosphate (alum adjuvant) and calcium phosphate. Alum 
has historically served as immunopotentiaters in vaccine development and 
continued to be most widely used adjuvant (Lindblad 1995). Alum has a good 
safety record, but comparative studies show that it is a weak adjuvant for 
antibody induction to protein subunits and a poor adjuvant for cell-mediated 
immunity. Not to be on very positive side, alum adjuvants can induce 
immunoglobulin E (IgE) antibody responses and have been associated with 
some allergic reactions in human subjects (Gupta 1998, Relyveld et. al .1998). 
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Table 2 
Selected examples of vaccine adjuvants 
Adjuvant type 
Mineral salts 
Microbial 
Particulate 
Oil emulsions & surfactant-based 
Synthetic 
Cytokines 
Genetic 
General examples 
Aluminium hydroxide/phosphate, 
Calcium phosphate 
Muramyl dipeptide, bacterial 
exotoxins (e.g. cholera toxin, heat 
labile enterotoxin)/ endotoxins (e.g. 
monophosphoryl lipid A, bacterial 
DNA (e.g. CpG motif) 
Microspheres, ISCOMS, liposomes, 
niosome, virosomes. 
Freunds adjuvant, MF 59, SAF 
Saponins (e.g. QS 21), Muramyl 
peptide derivatives, non-ionic block 
co-polymers, synthetic 
polynucleotides 
IL-2, IL-12, GM-CSF, IFN-y 
Cytokine genes or genes encoding 
costimulatory molecules delivered as 
plasmid DNA 
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1.1 Microbial components 
2.2.1 Muramyl dipeptide 
N- acetyl muramyl-1 alanyl-D isoglutamine is smallest subunit of the 
mycobacterial cell wall that retains immunoadjuvant activity and referred as 
Muramyl di Peptide (MDP). MDP solution administered in saline induces 
humoral immune responses mainly, while water in oil emulsion (eg. Syntax, 
emulsion of threonyl MDP and squaline) increases antibody and cell 
mediated immunity (Ellouz et. al. 1974, Warren et. al. 1986). 
2.2.2 Monophosphoryl lipid A 
Monophosphoryl lipid A is less toxic adjuvant active derivative of 
lipopolysaccharide (Ribi et. a/. 1984). MLA promotes IFN-y production by 
T-cells and thus indirectly aids in production of antibodies (Tomai & 
Jhonson 1989). MLA preferentially triggers Th-1 cells and direct secretion 
of IgG2a isotype (Takayama et. al. 1991). Because of its safety and 
extensive clinical evaluation, MPL is strong candidate for use as an adjuvant 
for human preventive and therapeutic vaccines against infectious and 
neoplastic diseases. 
2.2.3 Bacterial DNA 
One of the most promising classes of new adjuvant is the 
immunostimulatory sequence in bacterial DNA. These are short nucleotide 
of DNA containing unmethylated guanine and cytosine dinucleotides, so 
called CpG motifs. They trigger B-cell activation and induce cytokine 
response leading to Th-1 response. CpG oligodeoxynucleotides work for 
both systemic and mucosally administered antigens (McCluskie & Davis 
2000,Weeratna et. al. 2000). 
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2.3 Cytokines 
Several cytokines have been used as experimental vaccine adjuvants, 
including IL-2 and IFN- y (Nohria &Rubin 1994). IL-12 is recently 
characterized cytokine whose adjuvant activity has been demonstrated 
against leishmaniasis (Schott & Trinchieri 1997). Cytokine mixtures, 
including GM-CSF, TNF-a and IL-12 emulsified in IF A have also been 
employed to steer the immune response in desired direction (Ahlers et. al. 
1997). 
2.4 Oil emulsion and surfactant based adjuvant 
2.4.1. Freunds Adjuvant 
The powerful immunologic adjuvant is composed of a water-in-
mineral oil emulsion and containing killed mycobacteria as an additional 
immunomodulator (Freund et.al 1937). This adjuvant is known as Freund's 
complete adjuvant (FCA). Although FCA is one of the most effective 
adjuvants known, is highly reactogenic and cannot be used in human 
vaccines. However, Freund's incomplete adjuvant (FIA), which does not 
contain mycobacteria was employed in an influenza vaccine licensed in the 
United Kingdom and is used in several HIV vaccines under clinical 
evaluation (Jansen et. al 1998). 
2.4.2. MF59 Adjuvant 
MF59 is oil in water microfluidised emulsion composed of stable 
droplets (250nm) of the metabolizable oil squaline (4.3% w/v) and two-
surfactant polyoxyethylene sorbitan monooleate (Tween 80; 0.5% w/v) and 
sorbitan trioleate (Span 85; 0.5% w/v). MF59 is safe, practical and potent 
adjuvant for use with human vaccines, with more than five million doses 
distributed. The adjuvant has been shown both in animal models and in 
humans to be a potent stimulator of cellular and humoral responses to 
subunit antigens. Toxicology studies in animal models and phase I through 
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IV studies in humans have demonstrated the safety of MF59 with HSV, HIV, 
and influenza vaccines (Podda 2001,Ott et. al. 1995). 
3. The role of adjuvants in vaccine development 
Adjuvants can be used to improve the immune response to vaccine 
antigens in several different ways: 
(1) adjuvants can increase the immunogenicity of weak antigens; 
(2) enhance the speed and duration of the immune response; 
(3) modulate antibody avidity, specificity, isotype or subclass distribution; 
(4) stimulate CMI; 
(5) promote the induction of mucosal immunity; 
(6) enhance immune responses in immunologically immature, or senescent 
individuals; 
(7) decrease the dose of antigen in the vaccine and reduce costs 
(8) help to overcome antigen competition in combination vaccines. 
The mechanisms of action of most adjuvants still remain only 
poorly understood, and this has impeded the rational development of new 
adjuvants. Immunization often activates a complex cascade of responses, 
and the primary effect of the adjuvant is often difficult to clearly discern in 
vivo. However, if one accepts the recently proposed geographical concept of 
immune reactivity, in which antigens, which do not reach the local lymph 
nodes, do not induce responses, it becomes easier to propose mechanistic 
interpretations of the important effects of some adjuvants (Janeway & 
Medzhitov 1998, Bretscher & Cohn 1970). If antigen fails to induce 
desirable immune response , co-administration of adjuvant may help in 
enhanced delivery of antigen for activation of desirable immune response. 
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Antigen delivery may be enhanced in several ways; the adjuvant may 
increase cellular infiltration into the injection site, so that more cells can 
take up antigen, it may directly promote the uptake of antigen into antigen 
presenting cells (APC), or it may contribute to the delivery of antigen to the 
local lymph nodes. Following uptake of antigen and cell activation, APCs 
undergo maturation and migrate to lymph nodes, where they have the unique 
capacity to present antigens to naive T cells. Hence, the principal mode of 
action of a range of particulate adjuvants, or 'antigen delivery systems' e.g. 
microparticles, emulsions, liposomes, ISCOMS etc. may be to promote 
uptake of the antigen by APC at the injection site. The most appropriate 
adjuvant to use for a given vaccine antigen will depend to a large extent on 
the type of immune response that is required for protective immunity. 
However, for many infectious diseases, the correlates of protective immunity 
have yet to be established. Therefore, in many situations, adjuvant selection 
remains rather empirical. 
4. An immunologic perspective on adjuvants 
Immune protection following vaccination depends predominantly on 
the generation of immunologic memory, mediated by B and T lymphocytes 
of the acquired immune system, which have highly restricted antigen 
specificity. Vaccines are effective either due to prevention of infection, or to 
prevention of disease. Antibodies are thought to be most important for 
prevention of infection, but this might be very difficult to be of any utility 
against some pathogens e.g. HIV. In contrast, T cells are mainly responsible 
for recognizing and killing infected cells and function to limit the spread of 
infection. For most pathogens, the initial infections can be successfully 
eradicated by the immune response, or the infection is inherently self-
limiting. However, some pathogens are successful at establishing a reservoir 
of infection that is very difficult to clear e.g. HIV and HCV. Potent 
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adjuvants and novel vaccine strategies may be required to allow the 
successful elimination of these reservoirs. 
The dominant paradigm in immunology for several decades was that 
the immune system evolved to discriminate self from non-self (Janeway 
1989). This hypothesis resulted in significant progress in understanding the 
clonal recognition of antigenic epitopes mediated by B and T lymphocytes. 
However, the self/non-self framework offers little insight into why some 
non-self antigens are found to be poorly immunogenic. In the last decade, 
alternative models of immunity have been established, which emphasize the 
selective pressures on the host to induce a pro-inflammatory innate immune 
response to Pathogen Associated Molecular Patterns [PAMP's] (Medzhitov 
& Janeway 1997, Matzinger 1994) and tissue damage (Matzinger 1998, Shi 
et. a/. 2000, Pearson 1997, Pearson & Locksley 1996). These more ancient 
responses are not antigen-specific and are mediated by the innate immune 
system (Pearson & Locksley 1996). In this new model of immunity, vaccines 
will elicit a potent immune response only when the nonself antigens mimic 
key aspects of infectious agents or cause some degree of localized tissue 
damage. Traditional vaccines such as bacterial toxoids and attenuated viral 
vaccines often contain all or most of the features of real pathogens and 
therefore, are sufficiently potent to induce protective immune responses. In 
contrast, recombinant vaccines are highly purified, lack many of the features 
of the original pathogen and do not evoke strong immune responses. 
Therefore, Vaccine adjuvants are crucial to make the vaccine sufficiently 
immunogenic. Hence it can be argued that the role of vaccine adjuvants for 
recombinant vaccines is to ensure that the vaccine resembles infection 
closely enough to initiate a potent immune response. In addition, the innate 
immune system directs the balance of humoral and CMI and adjuvants can 
control the type of acquired immune response induced. 
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5. Particulate antigen delivery systems 
Several groups have evaluated the use of particulate adjuvants, or 
antigen delivery systems, as alternatives to immunostimulatory adjuvants. 
Particulate adjuvants (e.g. emulsions, microparticles, ISCOMs, liposomes, 
virosomes and virus-like particles) have comparable dimensions to the 
pathogens, which the immune system evolved to combat (Table 3), 
Immunostimulatory adjuvants may also be included in particulate delivery 
systems to enhance the level of response, or to focus the response through a 
desired pathway, e.g. Thl or Th2. In addition, formulating potent 
immunostimulator adjuvants into delivery systems may limit adverse events, 
through restricting the systemic circulation of the adjuvant. Some of the 
particulate antigen delivery system employed in vaccine development is 
discussed below 
Table 3 
A comparison of the relative dimensions of pathogens and 
particulate adjuvants: 
Natural pathogens Size Particulate adjuvants Size 
Bacteria 
Poxvirus 
Herpesvirus 
HIV 
Influenza virus 
Poliovirus 
Parvovirus 
0.5-3 ^m 
250 nm 
250 nm 
100 nm 
100 nm 
20-30 nm 
20-30 nm 
Microparticles 
Liposomes 
Virosomes 
MF59 
ISCOMS 
Virus-like particles 
lOOnm-lO^im 
50 nm-10 nm 
50 nm-10 |im 
200 nm 
40 nm 
20-50 nm 
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5.1 Liposomes 
Liposomes offer an alternative, versatile and universal adjuvant 
system with high safety profiles. Liposomal immunoadjuvants passively 
accumulate within regional lymph nodes and act as antigen depot by slowly 
releasing encapsulated antigenic components. Table 4 provides list of 
antigens with which liposomes have been used. Liposomes have been firmly 
established as immunoadjuvants by potentiating both antigen specific 
humoral (Alving et al, 1995) as well as cell-mediated immunity (Owais and 
Gupta, 2000). 
Some other advantages of using liposomes for immunopotentiation 
are as follows: 
• A non-immunogenie substance may be transformed to an immunogenic 
one. 
• Hydrophobic antigens may be reconstituted. 
• May incorporate multiple antigens and other adjuvants to provide strong 
immune response. 
• Toxicity of the antigens can be reduced or may be eliminated by 
inclusion into the liposomes. 
• Modulation of the immune system. 
f 
• Liposomal vaccines produce higher titers of functional antibodies as well 
as prolonged duration of these antibodies. 
5.1.1 Liposomal Vaccines 
Liposomal vaccines can be developed by incorporating microbes, 
soluble antigens, cytokines or deoxyribonucleic acid in liposomes. 
Alternatively, antigens can be covalently coupled to liposomal membrane for 
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increasing their immunogenicity (Wassef et ai, 1994). Also for enhanced 
immunopotentiation, some other agents such as muramyl dipeptide (MDP), 
lipopolysachharide, lipid A and tuftsin can also be incorporated into 
liposomes (Schroit and Fidler, 1986; Singhal etal, 1984; Bennett-Guerrero 
et al, 2000; Richards et al, 1998). Some of the commercially available 
liposomal vaccines are enlisted in Table 5. The first liposome based vaccine 
(against hepatitis A) for human use is IRIV vaccine produced by Swiss 
serum and vaccine institute, Berne, Switzerland known as "Epaxal-Berna 
Vaccine" (Gluck, 1995). 
Table 4 
List of Antigens with which liposomes have been used as 
immunoadjuvants. 
ANTIGEN 
Influenza subunit antigen 
Bacterial polysaccharide 
Rabies glycoprotein 
Polio virus peptides 
Cholera toxin 
Toxoid of B. pertussis 
Tetanus toxoid 
Diphtheria toxoid 
Herpes simplex virus 
Hepatitis B virus surface antigen 
LIPOSOME / EFFECT 
Intranasal, protects animals from virus 
Superior immunoadjuvants 
Ag specific IL-2 enhancement 
Enhanced Antibody level 
Superior immunoadjuvants 
Very effective vaccine 
Mannose-mediated liposomal targeting, 
increased antibody titer 
Higher Antibody response 
MLV with lipid A, Enhanced Antibody level 
Humoral and cellular immunity 
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TABLE 5 
Liposome based vaccines either approved or licensed for use in 
human 
SYSTEM 
Novasomes 
Novasomes 
Novasomes 
Novasomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
COMPONENTS 
Killed new castle disease virus 
Killed avian retrovirus 
E.coli0157:H7 (killed) 
Shigella flexneri 
Haemagglutinins/neuraminidase 
from influenza strains 
Inactivated hepatitis A virions 
Genetically engineered Hepatitis 
A and B components(HAV) 
Diptheria and tetanus toxoids 
Diptheria and tetanus toxoids 
+HAV virions 
TARGET 
DISEASE 
New castle 
disease 
Retroviral 
infection 
£. CO//0517 
infections 
S. flexneri 
infections 
Influenza 
Hepatitis A 
HepatitisA 
andB 
Diptheria and 
tetanus 
Diptheria, 
Tetanus, 
HepatitisA 
andB 
COMPANY 
IGI, Vineland 
Lab, NJ, USA 
IGI, Vineland 
Lab, NJ, USA 
Novavax, USA 
Novavax, USA 
Swiss serum and 
Vaccine 
Int.,Switz. 
Swiss serum and 
Vaccine Int, 
Switz. 
Swiss serum and 
Vaccine Int., 
Switz 
Swiss serum and 
Vaccine Int., 
Switz 
Swiss serum and 
Vaccine Int., 
Switz 
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5.2 Microsphere 
Among various polymeric systems developed as pharmaceutical 
dosage forms, poly-lactide co- glycolide (PLGA) microspheres have been 
widely explored in several immunological studies as a controlled delivery 
system of peptides, native and synthetic proteins and lately, nucleic acids 
(Eldridge et. al. 1991, O. Hagan et. al. 1993, Partidos et. al 1994). PLGA 
microspheres are composed of a spherical shaped polymeric matrix ranging 
in diameter from 1 to 250 jim. The prerequisite factors important for such 
delivery systems are: 
i) ability to release the entrapped substance in a controlled way, which 
is influenced by polymer molecular weight, monomer ratio and 
morphology (Dorta et. al 1993, Park 1994); 
ii) particle size, which is important in terms of interaction with 
phagocytic cells (Eldridge et. al. 1991, Eldridge et. al. 1991); 
iii) safety, which is related to the in vivo polymer degradation and 
iv) stability, both in terms of shelf life and in the biological fluids 
(Pistnere/. al.1993). 
The biodegradable and biocompatible polyesters, the polylactide-co-
glycolides (PLG) are the primary candidates for the development of 
microparticles as adjuvants, since they have been used in humans for many 
years as suture material and as controlled release drug delivery systems. 
However, the adjuvant effect achieved through the encapsulation of 
antigens into PLG microparticles has been demonstrated only relatively 
recently (Partidos et. al. 1994). Microparticles with entrapped antigens 
(ovalbumin (OVA) and staphylococcal B enterotoxoid) had comparable 
immunogenicity to these antigens dispersed in Freund's adjuvant, the most 
potent adjuvant available (Eldridge et. al. 1991, Maloy et. al. 1994). Recent 
studies have shown that microparticles also exert an adjuvant effect for the 
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induction of cell-mediated immunity (Moore et. al. 1995). Microparticles 
also appear to have significant potential as an adjuvant for DNA vaccines 
(Jones et. al. 1997). The adjuvant effect of microparticles appears to be 
largely a consequence of their uptake into DC, macrophages and local 
lymph nodes following intramuscular injection. A particularly attractive 
feature of microparticles is their ability to control the rate of release of 
entrapped antigens. Controlled release of antigen may allow the 
development of single dose vaccines, which would result in improved 
vaccine compliance, particularly in the developing world. Although 
microparticles have significant potential for the development of single dose 
vaccines, much work is needed to ensure the stability of antigens entrapped 
in microparticles. 
5.3 Immune Stimulating Complex (ISCOMs) 
ISCOMs are spherical, micellar assemblies of about 40nm. They are 
made of the saponin mixture Quil A, cholesterol and phospholipids (Mowat 
& Donachie 1991). They contain amphiphilic antigens like membrane 
proteins. Quil A is a potent adjuvant that has been used as such in veterinary 
vaccines since the early 1970s. Results obtained with oral vaccination using 
ISCOM have been variable, showing partial protection/ clearance in some 
systems (Behbaudi et al. 1996,Dotsika et. al. 1997). ISCOM based vaccines 
also have the ability to induce CTL which may be important in the 
protection / recovery from viral as well as other intracellular pathogens. The 
induction of CTL against specific antigens has been demonstrated for a 
number of ISCOM based vaccines in both mice and non-human primates 
(Maloy et. al. 1995, Takahashi et. al. 1990)). Apart from parenteral 
immunisation, ISCOMs have been used for mucosal delivery of antigens 
(Mowat & Donachie 1991). They are able to boost both humoral and cellular 
responses. Antigens from viral, bacterial and parasitic sources have been 
studied. ISCOMs are able to generate a broad range of immune responses. 
28 
^ievietO'<»^£i6e«vUure 
These include APC activation (Behbaudi et. al. 1996), increased MHC II 
expression on APCs, cytokine induction, especially IL-2 and IFN-y (Dotsika 
et. al. 1997), CD4'' T-cell responses (Maloy et. al. 1995) and CDS"" CTL 
responses (Takahashi et. al. 1990). At the moment, one ISCOM vaccine is 
licensed. It is an anti-influenza vaccine to be used for horses. More than 1 
million doses have been sold in Sweden. A human phase I study with 
ISCOM-matrix caused mild pain at the injection site (Barr et. al. 1998). 
6. Fusogenic Liposomes 
Fusogenic liposomes can potentially facilitate the intracellular 
delivery of encapsulated molecules (drugs or antigen) by fusing with the 
target cell. A variety of approaches can be envisioned for constructing 
fusogenic liposomes. Examples include the inclusion of lipids that are able 
to form non-bilayer phases, such as DOPE, which can promote 
destabilization of the bilayer, inducing membrane-membrane fusion (Ellens 
et.al. 1986, Ellens et. al. 1986). Furthermore, alterations in the lipid 
composition can render liposomes pH sensitive, leading to enhanced 
fusogenic tendencies in low pH compartments such as endosomes (Wang & 
Huang 1989, Tari et. al. 1993). Non-phospholipid fusogenic liposomes 
composed primarily of dioxyethylene acyl ethers and cholesterol have been 
shown to fuse with plasma membranes of erythrocytes and fibroblasts 
(Baraka et. al. 1996). Alternatively, efficient fusogenic liposomes can be 
achieved by incorporating fusogenic proteins into the liposome membrane 
(Fiebre et. al. 1993, Compagnon et. al. 1992, Bron et. al. 1994) or entrapped 
within liposomes (Glushakova et. al. 1992). The feasibility of this approach 
has been demonstrated for the delivery of the diphtheria toxin A subunit 
using liposomes produced from influenza virus envelopes (Bron et. al. 
1994). Fusogenic peptides can be conjugated to the liposomes and may also 
promote intracellular delivery (Lee et. al. 1996, Kato et. al. 1991, Puyal et. 
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al. 1994). Some of the fusogenic liposomes presently employed in drug and 
vaccine delivery are discussed below. 
6.1 Virosome 
Immunostimulating reconstituted influenza virosomes (IRIVs) are 
spherical, unilamellar vesicles with a mean diameter of approx. 150 nm. 
IRIVs are prepared by detergent removal from influenza surface 
glycoproteins and a mixture of natural and synthetic phospholipids 
containing 70% egg yolk phosphatidylcholine (EYPC), 20% 
phosphatidylethanolamine (PE) and 10% envelope phospholipids originating 
from HlNl influenza virus. The influenza hemaglutinin intercalated in 
liposomal bilayer is responsible for fusion of liposome with endosomal 
membrane (Tsurudome et. al, 1992). The specific fusion mechanism allows 
targeting of the MHC I or the MHC II class pathway. Antigens linked to the 
surface of virosomes are degraded upon the endosomal fusion within the 
endosome and are presented to the immune system by MHC II class 
receptors. If the antigens are encapsulated in the virosomes, the antigens 
will be delivered to the cytosol and will enter the MHC class I pathway. 
Therefore, virosomes are able to induce either a B- or T-cell immune 
response. The first liposomal vaccine for human use was licensed in 1996, a 
virosomal hepatitis A vaccine (HAV) and is now registered in nearly all 
countries of the EU, the Americas and Asia (Holzer et. al. 1996). The 
virosomal HAV vaccine is able to induce a very fast immune response, 
100% of seroconversion has been achieved within 10 days of immunization 
(Abrosch et. al. 1998). In addition to the excellent tolerability, a very good 
long-term protection could also be shown (Holzer et. al. 1996). In a placebo 
controlled field trial, the HAV-IRIV vaccine has proven its efficacy 
(Mayorga et. al. 1997). A trivalent, IRIV-formulated influenza vaccine has 
shown a very good immunogenicity in all age groups and also excellent 
tolerability (Conne et. al. 1997). These IRIV-based vaccines are safe and do 
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not engender any anti-phospholipid antibodies against the liposome 
components of the IRIV (Cryz et. al. 1996). The IRIV adjuvant represents 
the first alternative to the problematic old chemical aluminum salts 
(Zrubriggen & Gluck 1999). The inherent property of virosome aid in 
activation of both humoral and cell mediated immune response. It has been 
demonstrated, that a synthetic peptide, enclosed in virosomes is able to 
induce a CTL immune response in mice (Arkema et. al. 2000). Therefore, 
the IRIV-based formulations appeared to be superior to the alum-based 
vaccines in terms of immunogenicity as well as prophylactic potential. 
6.2 Archaeosome 
Archeosomes are liposomes made up of total polar lipids isolated 
from various archebacteria (Patel & Sprott 1999). Archeosome display 
several unique properties including enhanced stability against extremes of 
pH, oxidation, elevated temperature and action of lipases that might be 
expected to impart superior properties to them for certain biotechnological 
applications (Sprott 1992, Choquet et. al. 1994, Sprott et. al. 1996) 
Archeosomes induce strong humoral , cell mediated and memory responses 
(Krishnan et. al. 2000). Moreover both humoral and cell mediated immune 
response generated by archeosome was found to be superior than 
conventional liposomes, alum and freunds adjuvant (Conlan et. al. 2001). 
The soluble antigen entrapped in archeosome were able to induce antigen 
specific CD8+ cytotoxic T lymhocytes (Krishnan et. al. 2000). Archeosome 
were able to impart protective immunity against facultative intracellular 
pathogen Listeria monocytogenes (Conlan et. al. 2001). 
7. Other Antigen delivery systems 
7.1 Nlosome 
These are small unilamellar vesicles made from non-ionic surfactants. 
They are also called non-ionic surfactant vesicles (NISV) or Novasomes 
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(Brewer & Alexander 1994, Gupta et. al. 1996). BSA in niosomes was 
shown to be as immunogenic as BSA with Complete Freund's adjuvant 
(Brewer & Alexander 1992). The chemical stability of niosomes is higher 
than the stability of phospholipid liposomes. Non-ionic surfactant vesicles 
have clearly demonstrated their ability to function as adjuvants following 
parenteral administration with a number of different antigens and peptides 
such as OVA (Brewer, Roberts et al. 1996), BSA (Brewer and Alexander 
1992), a soluble T. gondii antigen (Roberts, Brewer et al. 1994), a synthetic 
measles peptide (Brewer, Roberts et al. 1996) and HSV-1 (Hassan, Brewer et 
al. 1996). Results from these studies have suggested that the immune 
responses preferentially activated by NISV are of the Thl- type, and this is 
particularly useful for vaccines directed against intracellular pathogens, 
which generally require cell mediated immune responses. NISV have been 
reported to possess extremely low toxicity and enhanced stability hence they 
appear to be excellent candidates for further development as vaccine 
adjuvants (Roberts, Brewer et al. 1994). 
7.2 Cochleates 
Cochleates are composed of simple, naturally occurring materials; 
phosphatidylserine (PS), cholesterol and calcium. They are stable 
phospholipid-calcium precipitates, which are structurally distinct from 
liposomes (Papahadjopolus.e/. al. 1975). Their unique structure consists of a 
large, continuous, solid, lipid bilayer sheet rolled up in a spiral, with no 
internal aqueous space, Cochleate formulations have been shown to be 
simple, safe and highly efficacious mediators of the in vivo delivery of 
proteins, peptides and DNA for the induction of antigen-specific immune 
responses following oral, intranasal and intramuscular administration 
(Gould-Fogerite & Mannino 1995, 1996). Strong, long-lasting, mucosal and 
circulating antibody responses are generated (Michaleck et. al. 1998). 
Protection from challenge with live viruses following oral or intra muscular 
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administration has been achieved (Gould-Fogerite et. al. 1998). Thus, this 
delivery technology appears to be well suited for use with subunit vaccines. 
8. The cardinal Th-1 response 
CD4+ T cells recognize antigens after they have been processed 
through the exogenous pathway by APC, expressing major 
histocompatability complex class II (MHC II) molecules. After activation, 
CD4+T cells differentiate into functional subsets, termed T helper 1 (Thl) 
and Th2. The dichotomy of various cytokines secreted in the host is largely 
regulated at different levels (Cherwinsky et. al. 1987, Mosmann & Moore 
1991,Romagnani 1991). Thl responses are typically characterized by the 
secretion of IFN-y and the generation of delayed type-hypersensitivity 
responses. Thl cells are thought to mediate the killing of intracellular 
pathogens, mainly through IFN-y. The production of Thl responses appears 
to be crucially dependent on IL-12 production, which is produced by 
phagocytic APC, following exposure to pathogens. In contrast, Th2 
responses are characterized by the secretion of IL-4, IL-5, IL-6 and IL-10, 
and help in the induction of high levels of circulating antibodies. The 
different cytokine secretion pathways appear to be mutually antagonistic to 
some extent, and upregulation of one type of response normally results in 
down-regulation of the alternative. In mice, the production of the IgG2a 
antibody isotype is widely recognized as charactieristic of a Thl response, 
while a Th2 response is associated with the induction of IgGl (Snapper & 
Paul 1987). There are strong indications that cytokines produced by DC 
following their activation or maturation directly influence T helper cytokine 
profiles, i.e. the development of Thl vs. Th2 responses (Bottomly 1999). 
Although different adjuvants may induce comparable levels of functional 
antibodies, the respective cytokine profiles and antibody isotypes may 
differ. In certain situations, the type of response induced (Thl or Th2), may 
have a significant impact on the protective efficacy of a vaccine. Different 
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adjuvants tend to favor specific types of responses and this may provide 
some degree of guidance in adjuvant selection. However, adjuvant choice is 
often complicated by commercial constraints, toxicity and availability. 
CDS^ T^ cells recognize antigens that are processed endogenously and 
presented by cells expressing MHC class I molecules. CD8^T cells mediate 
their effector function through the production of cytokines, such as IFN-y 
and TNF-a, and through a direct cytolytic effect. The cytolytic effect of 
CDS'^ CTL is mediated by the release of granule contents, such as perforin 
and granzyme. In addition, CDS'^ CTL can kill the target cells by a process of 
Fas-mediated lysis. 
9. Intracellular Survival strategies of pathogen 
The multifaceted dialogue between intracellular pathogen and 
mammalian host continues to be an exciting issue not only from scientific 
but also public health viewpoint. The host microbe relationship is a dynamic 
process in which the microbe attempts to minimize its visibility to ensure 
survival, whereas the host attempts to prevent and eradicate infection with 
minimal damage to self (Janaway et. al, 2002). It is widely acknowledged 
that intracellular pathogen have developed shrewd strategies to evade the 
host defenses so as to survive and replicate and use host resources for its 
survival and persistence (Kauffman 1993). According to WHO infectious 
diseases is worlds largest killer of children and young adults (WHO, 1999). 
The importance of professional phagocytes in acquired resistance against 
infectious diseases is well established. These phagocytes play key role in 
distinguishing between plethoras of microbial invaders from self and 
inducing the acquired immune response best suited against particular 
pathogen (Metchnikoff, 1905). Acquisition of resistance against intracellular 
pathogen crucially depends on T lymphocytes. The T cell requisite is best 
exemplified by the high incidence of intracellular infections in patients 
suffering from T- cell deficiencies particularly AtDS (Benito et. al, 2004). 
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10. Vaccines against intracellular infection 
Immunity to different infectious diseases requires distinct types of 
immune reactions, which have to be evoked by differently, designed 
vaccines. However it is well established that an effective vaccine against 
intracellular pathogen is the one that is capable of activating apart from 
humoral immune response a strong cellular immune response. Despite the 
fact that neutralization of infectivity of challenge is critical role for specific 
antibody, some infectious agent escapes neutralization and replicate in the 
host cells. However, considerable numbers of literatures have well 
documented the role of antibody in clearance of intracellular infection 
(Plotkin 2001, Taylor 1994). Interestingly several workers have shown the 
persistence of infection in presence of high titre of antibodies (Ramphal et. 
al. 1979). Thus the role of antibody alone in completely preventing the 
intracellular infection cannot be advocated. 
The importance of cell-mediated immune response against 
intracellular infection is well supported by the fact that animals deficient in 
genes for IFN-y or IL-12 or functionally depleted CD8+ T cells have all 
been shown to be increasingly susceptible to the infection with accelerated 
mortality (Heinzel et.al. 1993, Sypek et. al. 1993). 
11. Salmonella Infection 
Salmonellae comprise a family of enteric pathogens characterized as 
facultative intracellular bacteria capable of inducing a range of systemic 
diseases, including typhoid fever, gastro-enteritis and bacteremia in humans 
and animal hosts. Typhoid fever is public health problem of which there are 
an estimated 33 million cases and resulting 500,000 deaths each year 
worldwide (Huckstep 1962, Ivanoff & Levine 1997). 
35 
3rietdea>of^LMe9vUtM^ 
11.1 Epidemiology 
The infection is transmitted when susceptible host ingests food and 
water that has been contaminated by faecal matter. In contrast transmission 
through person to person by direct contact is exceedingly uncommon. As a 
consequence of these epidemiological feature typhoid fever represents the 
infectious disease for which transmission is related to levels of sanitation 
and quality of water supply (Wolman & Garman 1931). Typhoid fever can 
abound wherever sanitation and food hygiene is primitive. Typhoid fever 
remains endemic in most of the less developed areas of the world, where 
fecal contamination of water sources still occurs. This includes many 
countries in Africa, Asia and Latin America. 
11.2 Pathogenesis 
Upon entering suitable host. Salmonella species like S typhi that are 
host adapted establish infection by sequentially surviving the acidic pH of 
the stomach competing with the normal bacterial flora of the small bowel, 
and passing through the epithelial barrier to proliferate in payers patches and 
draining mesenteric lymph nodes (Callazo & Gallan 1997). In an 
immunologically naive host, primary barriers to successful bacterial 
replication are the nonspecific antimicrobial factors like complement and 
phagocytic cells, both polymorphs and macrophages. If these initial 
encounter with the hostile environment of the host is successful these 
microorganism will subsequently drain through the lymphatic to the thoracic 
duct into the blood and ultimately infect liver and spleen (Takeuchi 1967). 
The outcome of infection depends on number of factors including size of 
bacterial inoculum, the virulence of infecting salmonella strain, medical 
intervention, and the ability to mobilize immune defenses to respond to 
infection (Fig 1). 
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Fig 1 . Pathogenesis of Salmonella upon entering host 
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11.3 Clinical Symptoms 
Typhoid fever exhibits wide range of clinical severity. Classical full-
blown cases begin with malaise, anorexia, mayalgia, fever that increases in 
stepwise fashion to reach 39°C to 40°C, abdominal discomfort and 
headaches (Huckstep 1962). A bronchitic cough is common at early stage of 
illness. Without appropriate antimicrobial therapy fever remains at this level 
for approximately 10-14 days. Rose spots are seen most often on chest, 
abdomen and back (Oilman et. al. 1975). The peripheral leukocyte count is 
often below 4500mm'', which help in differential diagnosis. 
Thrombocytopenia is also common with platelets drooping below 
80,000/mm''. Two of the most feared complications of typhoid fever 
viz.intestinal perforation and hemorrhage, are a consequence of the 
intestinal lesions that are so prominent in the pathology of S. typhi infection. 
Other common complications of typhoid fever include typhoid hepatitis, 
osteomyelitis and psychosis. More rarely arthritis, meningitis myocarditis 
and empyema of gall bladder can occur. 
11.4 Diagnosis 
Typhoid fever is confirmed either by bacteriologic or serodiagnosis. 
Confirmation of bacteriological diagnosis of typhoid fever requires recovery 
of S. typhi from a suitable clinical specimen. The gold standard confirmation 
is bone marrow culture, which is positive in 85% to 96% cases even when 
the patient has received antibiotics (Oilman et al 1975, Oeurra- Caceres et. 
al.1979). Stool cultures leads to recovery of organism in only 45% to 65% 
cases (Vallenas et. al. 1985). Serodiagnosis of typhoid fever is done through 
Widal test, which involves detection of 0 and H antibodies in patient serum 
(Widal & Sicard 1896). Serologic tests to measure Vi antibody is also 
available (Lanata et. al. 1983). The most recent test employed for diagnosis 
of Salmonella infection is Radio Immunoassay. The immunoassay are based 
on detection of O, Vi and other antigens ofS. typhi in blood or urine or other 
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body fluids using co-agglutination, ELISA or PCR (Barrett et. al. 1982). 
These assays aim to be more sensitive, practical economical and rapid than 
bacteriologic culture, however these tests have been disappointing and have 
failed to warrant the enthusiasm of initial reports. 
12. Typhoid vaccines 
The various typhoid vaccines can be grouped into three classes 
1. Vaccines that is no longer in use or under investigation. 
2. Vaccines that are currently available in various countries as licensed 
products, 
3. Future vaccines that are under active clinical evaluation. 
12.1 Early Vaccines 
Typhoid vaccines that were used earlier include 
12.1.1 Parenteral inactivated whole cell vaccines 
(a) Alcohol inactivated vaccine. The vaccine developed in 1940 was 
found to be superior because it preserved Vi antigen and out 
performed phenol preserved and heat inactivated vaccine in mouse 
protection assay. (Felix 1941) 
(b) Formalin inactivated, phenol preserved Vaccine. The vaccine 
was evaluated for efficacy in controlled field trial and prepared by 
inactivating S. typhi in formalin and preserved in phenol (Hejfec et. al. 
1966) 
(c) Acetone inactivated and dried vaccine. This type of vaccine 
preserves Vi antigen and improves stability on the long-term storage 
(Bull World, 1964). 
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12.1.2 Oral inactivated whole cell vaccine 
Killed 5. typhi or attenuated strains were used as oral vaccines to 
elicit local immunity. The oral inactivated whole cell vaccine evaluated in 
field trial or volunteer studies include acetone inactivated and formalin 
inactivated vaccine (Hejfets et. al. 1976). 
12.1.3 Parenteral or Aerosolized subunit vaccines 
A. Freeze and thaw extract vaccine. A parental vaccine prepared 
by the method of Grasset was assessed for efficacy in controlled 
field trial in Poland (Crassest 1951). 
8. Trypsinised extract vaccine. These vaccines were subjected to 
field trial of efficacy in Soviet Union and Poland (Topley et. al. 
1937). 
C. Purified lipopolysaccride vaccine. Two parenteral vaccines 
consisting of S. typhi LPS O antigen prepared from hot-water 
phenol extraction method were evaluated in Field trials in Poland 
and Soviet Union (Westphal et. al. 1952)> 
D. Purified Denatured Vi polysaccharide. This vaccine was never 
evaluated for efficacy in clinical trials due to denatured Vi antigen. 
However in experimental studies it conferred only modest (25% 
efficacy) and insignificant protection. (Landy 1954). 
12.1.4 Attenuated strains as live oral vaccines 
(I) Streptomycin dependent strains. The strain is developed by repeated 
cultivation of pathogenic Salmonella typhi in presence of streptomycin. The 
strains were unable to proliferate in absence of streptomycin. In volunteer 
challenge studies freshly isolated strain of streptomycin dependent oral 
vaccine proved to be highly protective whereas lyophilized preparations 
were not. (Rietman 1967) 
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(ii) Vi positive variant of Ty21a. The strain was well tolerated and had 
immunogenicity comparable to that of Ty21a in Phase I clinical trial. The 
protective efficacy of this vaccine strain was never evaluated in clinical 
trials (Cryz e/. al 1989). 
(iii) Vi negative strain of EX642. The strain was developed by removing 
internal; portion of galE from Ty2 and lacked Vi antigen. However two of 
the four volunteers developed typhoid fever when fed with this strain (Hone 
et. al. 1988) 
(iv) Strain G 2260. The strain is hybrid of 5. typhi and developed by 
incorporating chromosomal segments from E. coli K12 and S. flexeneri 2a. 
The oral vaccine was well tolerated and modestly immunogenic in a small 
Phase I study. Because no unimmunised control volunteers were 
concomitantly challenged, the stringency of the challenge model and level of 
vaccine efficacy cannot be ascertained (Dima 1983). 
(v) A aroA, A purA auxotrophic strain 541 Ty derived from wild type 
strain CDC10-80. The vaccine was prepared by mutating two genes of 
biosynthetic pathway in wild type S. typhi strain CDC10-80.The deletion 
mutation in aroA creates requirements for aromatic compounds that are not 
available in human tissues. The second deletion in purA causes specific 
requirement for adenine. These nutritional requirements render strain 541Ty 
unable to sustain growth in mammalian tissues. In Phase I clinical trials Ty 
541 was well tolerated but poorly immunogenic in eliciting serologic 
response to S. typhi antigens (Edwards 1984). 
(vi) 543Ty, Vi negative derivative of auxotrophic strain 541 Ty. The strain 
is spontaneously derived mutant of 541Ty that lacks the Vi polysaccharide 
capsular antigen. The vaccine is well tolerated but poorly immunogenic in 
elicting serologic response to S. typhi antigen in phase I clinical trials 
(Edwards 1984). 
41 
(vii) AaroC , AaroD double mutant recombinant strain CVD906.The 
strain was derived by precise deletions of 0.65 andO.35 kb fragment from aro 
C and aro D gene of wild type strain ISP 1820. This strain was evaluated in 
Phase I clinical trials and was found to be highly immunogenic with single 
oral dose but insufficiently attenuated. Febrile adverse reaction occurred in 
several vaccines (Hone et. a/. 1991). 
(viii) Acya, Acrp mutant strain x 3927. The strain was constructed by 
making deletion mutation in Acya and Acrp gene of 5. typhimurium, which 
were finally moved into wild type S.typhi strain Ty2. When evaluated in 
Phase I dose-response clinical trials x 3927 was moderately immunogenic 
but caused unacceptable febrile reaction in some subjects and so further 
clinical trials were discontinued (Curtis et. al. 1994, Tacket et al 1992). 
(ix) AaroA, AphoP/phoQ strain Ty445. The vaccine strain was constructed 
by introducing deletion mutations in AaroA and AphoP/phoQ into wild type 
strain CDC10-80.In Phase I clinical trial Ty445 was well tolerated but 
poorly immunogenic, leading to its abandonment from further development 
(Hohmaner. al. 1996) 
x) AaroA, AaroD strain PBCC211. The vaccine strain was constructed by 
introducing deletion mutations in two genes (AaroA and AaroD) encoding 
enzymes in aromatic acid biosynthesis pathway into wild type strain 
CDC 10-80. Three different formulation of this vaccine strain were tested in 
Phase I clinical trial. With two lyophillised formulations some subjects 
developed fever. At the highest dosage level tested a proportion of vaccinees 
manifested silent, self-limiting vaccinemias on days 4 to 5 after ingesting a 
single dose of vaccine. (Dilts et. al.2000). 
(xi) AaroA, AaroD, AhtrA strain PBCC222. The vaccine strain was 
derived by introducing deletion in htrA gene of PBCC211.The vaccine was 
evaluated in Phase I clinical trial. No vaccinemias were detected in 
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recipients of the strain but some who ingested the highest dosage level 
developed fever; chills and head ache leading to abandonment of further 
clinical trials (Dilts et. a/. 2000). 
These vaccines are no longer in use as they do not progress beyond 
clinical trials or large scale field trials because of unsatisfactory safety 
profiles, poor immunogenicity, disappointing efficacy relative to other 
typhoid vaccines, or difficulty in manufacture (eg. loss of potency following 
lyophillization). 
12.2. Currently licensed, available and used vaccines 
1. Heat inactivated, phenol preserved whole cell parenteral vaccine 
(both liquid and lyophillized formulations and occasionally adsorbed 
to alum adjuvant) 
2. Purified Vi polysaccharide parenteral vaccine 
3. Attenuated gal E, via (Vi negative) strain Ty21a, used as live oral 
vaccine 
12.2.1. Parenteral Inactivated Whole cell Vaccines 
Parenteral inactivated whole cell vaccines to prevent typhoid fever 
have been used since the end of 19'*' century (Pfieffer & Kolle 1896). The heat 
killed, phenol preserved vaccine is made by heating agar or broth grown S. 
typhi (usually to 56°C for 1 hr and then suspending them in 0.5% phenol 
solution, usually to concentration of lO' organism/ml). They are usually 
administered subcutaneously with 0.5ml injections containing 5X10* bacteria; 
two doses are given one month apart. Vaccine is stable for 30 months at 4°C 
in buffered saline solution and for 5 years as lyophilized form. The vaccine is 
able to activate primarily humoral immune response (antibodies against 0 , H 
and Vi antigen) and to lesser degree mucosal immune response (secretory 
IgA) and cell mediated immune response (Ashcroft et. al. 1964, Nisini 
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et. al. 1993, Rajgopalan et. al. 1982). The vaccine was found to be quite 
efficacious in controlled field trial (Tapa & Cvjetanovic 1975). Numbers of 
adverse events have been attributed to vaccination with parenteral killed 
whole cell vaccine, which includes thrombocytopenic purpura, acute renal 
disease, dermatomyositis, ependicitis, erythoma nodusum, multiple sclerosis 
and syndrome of high fever, severe malaise toximia and rarely death (Hoyt & 
Heripl996, Edwards et al. 1974). The longest period of surveillance was seven 
years and vaccine conferred 88% protection in Guyana and Tongo field trials 
(Ashcroft et. al. 1964). Primary immunization with this parenteral vaccine 
consists of two doses given four weeks apart; a single booster dose is 
recommended every three years. It is still available in several developing 
countries and is reasonably priced. In controlled trials the inactivated whole-
cell vaccine has reached protective efficacy rates of 51%-67%. However, in 
field trials the vaccine has been associated with fever and systemic reactions 
in 9%-34% of the recipients, and with short absences from work or school in 
2%-17% of cases. Apart from rare anaphylactic reactions, vaccine-induced 
fatalities or chronic disabling conditions have not been reported. 
12.2.2. Purified Vi Polysacctiaride Vaccine 
Vi Polysaccaride is extracted from Ty2 strain of S. typhi by detergent 
hexadecyltrimethylammonium bromide, which results in purified Vi that is 
not denatured and that preserves the O and N-acetyl moeties (Wong et. al. 
1974). This vaccine is composed of purified Vi polysaccharide from S. typhi. 
It is administered subcutaneously or intramuscularly as one dose of 25 mg to 
individuals under two years of age. The vaccine confers protection seven 
days after injection. Vi is further purified dried dissolved in buffer solution 
and filter sterilized. Vaccine is available as 25 ^g of purified polysaccharide 
in 0.5ml of phenolic isotonic buffer and is administered as single 
subcutaneous or intramuscular injection. Vaccine is more stable than whole 
cell inactivated vaccine and do not require cold conditions. Vaccine elicits 
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serum IgG Vi antibody response in approximately 85% to 95% of adults or 
children above two years of age (Klugman et. al. 1987, Tacket et. al. 1986). 
Vaccine conferred 55% efficacy when surveillance was maintained for three 
years in South African field trials (Klugman et. al. 1996). Vaccine is well 
tolerated when highly purified however less than 5% impurity of LPS results 
in adverse events like pain and tenderness at site of injection. Recommended 
storage temperature is between +1°C and +8*0. A randomized trial in Nepal 
involving persons aged 5-44 years showed 75% protection against culture-
positive typhoid fever during the 20 months of active surveillance. In a 
recent study in South Africa, 55% efficacy was demonstrated three years 
after immunization of children aged 5-16 years. Ten years after vaccination, 
58% still had >lmg ml-1 of anti-Vi IgG in their sera, a level frequently 
regarded as protective, although no consensus exists in this regard. 
However, a similar percentage of the controls had acquired the same levels 
of anti-Vi IgG over the 10-year period. Nevertheless, in areas of high 
endemicity the vaccine protected school-age children, usually considered the 
most susceptible age group. In regions of low disease endemicity, the 
duration of protection is uncertain. The vaccine is not effective in children 
under two years of age, and a study in Indonesia indicates that owing to poor 
responses, the vaccine is not cost-effective in children two to five years of 
age. To maintain protection, revaccination is recommended every three 
years. The Vi vaccine can be given simultaneously with other vaccines 
relevant for international travelers such as the vaccines against yellow fever 
and hepatitis A. There are no contraindications other than prior severe 
reaction to vaccine components. Although the vaccine is safe for HIV-
infected persons, the induction of protective antibodies is directly correlated 
to the levels of CD4 positive T-cells. Adverse reactions seem limited to 
fever (0%-l%), headache (1.5%-3%) and erythema or induration of more 
than 1 cm at the site of injection (7%). As with many other pure 
polysaccharide vaccines, no booster effect indicative of an immunological 
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memory is observed. For this reason, protein-Vi polysaccharide conjugate 
vaccines are being developed. 
12.2.3 Attenuated Ty21a oral vaccine 
Ty21a is derived from wild type Strain Ty2 by treatment with 
mutagenic agent nitrcsoguanidine. The mutant selected exhibited lack of 
enzyme UDP-galactose4 epimerase and reduction in activity of 
galactokinase and galactose-1-phosphate uridyl transferase. A further 
mutant, which also lacked Vi antigen, was selected and designated as Ty21a 
(Germmanier & Furerl975). Vaccine is available as enteric-coated capsules 
containing 2-6 x lO" CPU of Ty21a. A four dose oral immunization schedule 
is recommended in US whereas in other countries through out the world 
three dose regimen is used which is administered with an interval of one 
day. Vaccine is stable at 4°C for long-term storage however shelf life 
depends on residual moisture content and maintenance of cold chain (Cryz 
et. al. 1996). Vaccine was able to induce significantly enhanced antibody 
titre against O antigen. Moreover vaccinees showed a significant increase in 
sIgA against O antigen in jejunal fluid, serum, and saliva (Levine et. al. 
1989, Forest et. al. 1990). Fairly potent cell mediated immune response is 
stimulated by Ty21a vaccine which was measured by lymphocyte replication 
in presence of soluble or particulate antigen, inhibition of growth of S. typhi 
by mononuclear cells and detection of CTLs (Salerno-Goncalves et. al. 
2002). In field trial in Egypt vaccine conferred a high level protection (96%) 
that persisted for three years, the point at which surveillance was 
discontinued (Wahden et. al. 1982). Large-scale field trials with Ty21a 
involving 55000 school children in chile and 32000 in Egypt and 
approximately 20000 subjects ranging in age from 3 years to adulthood in 
Indonesia passive surveillance failed to identify vaccine related adverse 
events. (Simanjuntak et. a/. 1991). Ty21a is remarkably well tolerated. The 
vaccine may be given simultaneously with other vaccines, including live 
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vaccines against polio, cholera and yellow fever, or the measles, mumps and 
rubella (MMR) combination. Proguanil or antibiotics should be avoided 
during the three days before vaccination and afterwards. It is not known 
whether this live attenuated vaccine can cause fetal harm when administered 
to pregnant women. Ty21a can be administered to HIV-positive, 
asymptomatic individuals without risk as long as the T-cell count (CD4) is 
above 200/mm''. The vaccine requires storage between +2°C and +8*'C, 
Aiming at the development of more immunogenic oral vaccines against 
typhoid fever, several attenuated strains of 5. typhi other than Ty21a have 
been tested, or are currently undergoing testing. 
12.3. Future Vaccines 
"M.Z.^ Vi conjugates 
Because purified Vi polysaccharide acts T- lymphocyte independent 
antigen, the serum antibody response cannot be readily boosted by 
administration of additional doses of Vi vaccine. In contrast, when Vi is 
conjugated to carrier protein such as tetanus of diptheria toxoids, cholera 
toxin, cholera toxin B subunit it behaves as a T- lymphocyte dependent 
antigen (Szu et. al. 1987). In animal models subsequent inoculation with Vi 
conjugate vaccine clearly boosts the serum Vi antibody titer. The Vi 
conjugate vaccine (ISfig of Vi was covalently conjugated to E. coli LT B 
subunit or to recombinant exoprotein A of P. aeruginosa) was well tolerated 
and significantly more immunogenic than unconjugated purified Vi 
polysaccharide (Szu et. al. 1994). The conjugate was utilized in Phase III 
field trial of efficacy in Vietnam and showed high level efficacy (91.5%) 
conferred by two doses and is expected to be licensed in near future (Lin et. 
al. 2001). 
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12.3.2 New recombinant S. typhi strains as live oral vaccines 
These are new candidate vaccine strain of S. typhi that is well tolerated 
as Ty21a but much more immunogenic so that protective immunity can be 
elicited in single dose. Through application of recombinant DNA technology 
putative attenuated vaccine strains have been prepared by inactivating genes 
encoding various biochemical pathways, global regulatory systems, stress 
proteins and other regulatory genes and putative virulence factors (Hone et. 
al. 1988, Hindle et. al. 2002). Among these various strains, based on results 
of completed Phase I clinical trials, five strains remain viable vaccine 
candidates and are at various stages of clinical development as live oral 
typhoid vaccines or as live vectors. 
(a) ^aro C, Aaro D AhtrA strain CVD 908- Mr A. The vaccine is prepared 
by inactivation of htrA, a gene encoding stress protein that functions as 
serine protease, attenuates wild type S. typhimurium and protects orally 
immunized mice against challenge with wild type S. typhimurium (Chatfield 
et. al. 1992, Tacket et. al. 2000). The vaccine was found to be immunogenic 
and well tolerated in both Phase I and II clinical trials. 
(b) Strain x ^^73 with mutations in cya, crp, cdt The vaccine is 
attenuated strain of S. typi that harbor deletion mutation in cya (encoding 
adenylate cyclase), crp (encoding cyclic AMP receptor protein) and cdt 
(gene that effects dissemination of Salmonella from gut to deeper organs 
like liver, spleen and bone marrow (Curtis & Kelly 1994). The triple mutant 
X4073 was found to be effective and well tolerated. Moreover subjects 
exhibited significant rise in serum IgG O antibody and had ASCs that made 
IgA O antibody. 
(c) Strain Ty 800 with a mutation in pho P/pho Q. The vaccine is deletion 
mutant of Ty2 strain. It was well tolerated and immunogenic when evaluated 
in phase I clinical trial. At high dosage level one of three vaccinees 
48 
Wieme(» o^^LMettatiuie 
developed diarrhea. TySOO stimulated vigorous IgA ASCs and serum 0 
antibody responses (Hohmann et. al. 1996). 
(d) Aaro C, AssaV strain ZH9. The vaccine is double mutant of Ty2. The 
ssaV protein forms part of the S. enterica type III secretion system that plays 
role in virulence including affecting systemic effectiveness (in mouse 
model) and replication in macrophages. In Phase I clinical trial vaccine was 
well tolerated, minimally excreted, and moderately immunogenic (Hindle et. 
al. 2002). 
(e) Strain CVD 909. The peculiarity of this vaccine strain is that it 
constitutively expresses Vi polysaccharide as high level of protection may 
be attainable if a live oral vaccine can stimulate Vi antibody (like Vi and Vi 
conjugate vaccine) in addition to the other humoral and cellular responses 
elicited by oral vaccines like Ty21a. The vaccine strain is produced by 
replacing the promoter of tvi A, the most upstream gene in viaB locus 
(contains gene required for synthesis, surface transport and anchoring of Vi) 
with a strong promoter to derive strain CVD 909 which express Vi 
constitutively. Vaccine is under phase I clinical trial (Wang et. al. 2000). 
(f) AguaBA strains CVD 915 and CVD 916. CVD915 a AguaBA mutant of 
wild type strain Ty2 is poised to move into clinical trials. CVD 916 is 
constitutive Vi expressing variant of CVD 915 (Tacket et. al. 2000). 
Based on above mention studies I proposed to develop novel vaccine 
adjuvant escheriosome that can activate both humoral and cell mediated 
immunity to mount an effective immune response against intracellular 
infection. In the second part of the study I evaluated the efficacy of 
escheriosomes as vaccine adjuvant against intracellular pathogen S. 
typhimurium. 
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The use of vaccine for the prevention of microbial infection is 
preferred alternative to treatment. It has been applied successfully for 
instance in the eradication of small pox, tetanus, diphtheria, whooping 
cough, polio and measles, thus preventing million of death each year. 
Though effective for most of the diseases, the limitation associated with 
both killed and attenuated vaccine have always made scope to the 
development of more efficacious and better defined vaccine. In this pretext, 
subunit vaccines are designed to include the antigen required for protective 
immunization and to be safer than whole inactivated and live attenuated 
vaccine. However the purity of subunit antigen and absence of self-
adjuvanting immunomodulatory components associated with attenuated or 
killed vaccine often results in weaker immunogenicity of subunit vaccine. 
Immunological adjuvants have addressed these problems by enhancing 
specific immune response to these antigens. Although number of potent 
immunological adjuvants are available, however adverse reactions due to 
toxicity have limited their use in vaccine formulations (Allison & Byars, 
1991). Moreover, not to be on very positive note, these adjuvants are able to 
activate humoral immune response mainly and fail to activate significant 
level of cell-mediated immune response. Development of protective 
immunity against many pathogens, particularly viruses, requires fine 
orchestration of both humoral and cell mediated-immunity. The 
immunization of animals with soluble antigens usually leads to the induction 
of humoral immune responses. In contrast, the activation of a cell-mediated 
immune response against exogenous antigens has always been a challenge, 
requiring special strategies to expose them to the proteasome, a 
multifunctional protease complex in the cytosol of the target cells. The 
degradation of the protein by the cytosolic proteolytic system forms a 
cardinal step for the induction of cytotoxic T lymphocytes (CTLs). 
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CD4'' T helper and CD8^ T cytotoxic phenotype may be influenced by 
cytokine milieu, the differential expression of costimulatory molecules, 
antigen dose, differences in affinity at the TCR-peptide-MHC interface and 
adjuvants (Agrewala et. al. 1996, Agrewala & Wilkinson 1998, Braciale et. 
al. 1987, Liebana et. al. 1999). The induction of cell mediated immunity 
(CMI) to protein antigen is dependent on the activation of CD4'^, MHC class 
II (T-helper cells) and CD8^, MHC class I (cytotoxic T cells) restricted T 
cells (Braciale et. al. 1987, Unane & Allen 1987). T-helper cells (Th) 
facilitate cytotoxic T cell (CTL) and B cell responses, and help in the 
production of class switching and memory responses. Cytotoxic T cells 
represent the other effector arm of the cell-mediated immune response. T 
lymphocytes are of strategic importance in killing of the cells infected with 
intracellular pathogens and also towards surveillance mechanisms against 
cancer cells. The CD8"^  T cell phenotype can considerably influence the 
outcome of infection by intracellular pathogens. The role of cytotoxic T 
cells has been established and found to be crucial for protecting the host 
against diseases caused by intracellular microbes and viruses (Nickell et. al 
1993, Muller et. al. 1991, Flynn et. al. 1992, Deres et. a/. 1989). Since, both 
cytotoxic as well as T helper cells are crucial for protecting the host against 
intracellular pathogens, to mount an effective immunity against such 
infections, it is important to develop vaccines that generate strong CD4^ and 
CDS'" T cells responses (Flynn et. al. 1992, Tarleton et. al. 1992, Bottomly 
1988). 
A large number of structurally unrelated agents have been known for 
several decades to potentiate immune responses to weak vaccine antigens. 
Among these, best known are aluminium hydroxide (alum), saponins, 
Freund's complete and incomplete adjuvants, and more recently, 
lipopolysaccharide (LPS), muramyl dipeptide (MDP) derivatives, pluronic 
block co-polymers and liposomes (Gregoriadis et. al. 1989, Gregoriadis 
1994). Most of these adjuvants, however, are toxic. Therefore, concerted 
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efforts are being made to develop safe and effective adjuvants to meet the 
challenges of new-generation vaccines (Gregoriadis et. al 1991, Gregoriadis 
e/. a/. 1993). These should consist of inexpensive, non-toxic and non-
immunogenic materials, should be stable on storage, biodegradable and 
preferably promote both humoral and cell mediated immunity. In certain 
cases, they should also act synergistically together with other adjuvants (e.g. 
cytokines). Liposomes, also known for their potential and actual uses in 
targeted drug delivery, appear to satisfy many of these criteria (Gregoriadis 
1994, Gregoriadis 1988, Gregoriadis 1990). However, conventional 
liposomes in spite of being nontoxic and non-immunogenic lead to 
activation of humoral immune response mainly and fail to activate CTLs. In 
present scenario, where most of the infectious diseases are caused by 
intracellular pathogens, an ideal vaccine will be one, which can activate both 
branches of immune system for successful elimination of pathogen. In 
recent years fusogenic liposomes have attracted much greater attention for 
vaccine delivery as they have emerged as an improved vehicle for 
intracellular delivery of antigen and capable of activating both humoral and 
cellular immune responses (Reddy et. a/. 1991, Polt Frank et. al 1999).. 
The lipid composition of plasma membrane plays crucial role in many 
physiological activities, e.g. fertilization, phagocytosis, exocytosis and cell 
division especially in perspective of membrane-membrane fusion (Voet et. 
al. 1999, White 1992). Lower organisms, such as bacteria and yeast, have 
many fusogenic (anionic) phospholipids in their membranes, presumably to 
cope with the high multiplication rate (Krishnan et. al. 2000, Conlan et. 
a/. 2001, Rattray, Microbial lipids). Such lipids seem to facilitate the fusion 
of the two opposite sites of inner leaflets under physiological conditions. 
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Aim of the present work 
In the present study we have demonstrated that liposomes made up of 
E. coli lipid (escheriosomes) can emerge as effective vaccine adjuvant that 
can activate both humoral and cell mediated immune response (Fig 2). These 
liposomes redially fused with the membrane of the professional antigen 
presenting cells leading to the delivery of entrapped solutes to their cytosol. 
We found that antigen encapsulated in the escheriosomes could be readily 
introduced into the cytoplasmic as well as endosomal compartments of the 
target cells. The present study have revealed that antigen entrapped in these 
liposomes could generate strong OVA-specific, CD4'*' T-helper as well as 
CDS"^  cytotoxic T cells. The T-helper response was chiefly of Th-2 type, as 
evident from the secretion of IL-4 and IgGl-isotype.Moreover OVA 
encapsulated escheriosomes leads to enhanced secretion of Th-1 cytokines 
viz. IL-2 and IFN-y. On the contrary, the same antigen upon their 
encapsulation in egg PC liposomes induced humoral immune response 
mainly. 
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Animals 
Female Balb/c mice (8-10 weeks old), weighing 20 ± 2 g, were 
obtained from the Interdisciplinary Biotechnology Unit's Animal House 
Facility. The mice had ad libitium access to the pellet diet and drinking 
water. The experimental protocol was approved by the Institutional animals 
ethics committee. Ail the mice were housed under standard conditions at the 
Institute's animal facility. 
Chemicals and reagents 
All the reagents used in the study were of the highest purity 
available. We are thankful to Dr. CM. Gupta (Director, CDRI, Lucknow), 
Dr. G.C. Mishra (Director, NCCS, Pune), Dr. Amit Ghosh (Director 
IMTECH, Chd), Dr. J.N. Agrewala (Scientist,IMTECH, Chd), Dr. A.Puri 
(NIH, USA), Dr. A. Agrawal (Emory Vaccine Institute, USA) for their 
generosity and supply of various chemicals and cell lines used in the study. 
Cholesterol (Choi) was purchased from Centron Research Laboratory, 
Bombay, India, and crystallized three times with methanol prior to its use.. 
Peptone and yeast extract were from Hi Media Laboratories (Bombay, 
India), while dextrose was from S.D. Fine Chemicals (Boisar, India). 
Dulbecco's modified Eagle medium (DMEM), Hanks balanced salt solution 
(HBSS) and foetal bovine serum were obtained from Life Technologies 
(Grand Island, NY, USA). Ovalbumin (OVA), Sephadex G-50, Sepharose 
6B, and EDTA were all from Sigma Chemical Company (St Louis, MO, 
USA). Bicinchoninic acid protein assay Kit was from Pierce Chemical 
Company. J774 Al , a macrophage cell line, was purchased from American 
Type Culture Collection (Rockville, MD, USA) and was grown in DMEM 
(pH 7.2) containing L-glutamine (4 mM), sodium pyruvate (110 mg-L"'), 
penicillin (100 U-mL''), streptomycin sulfate (100 ng-mL'') and sodium 
bicarbonate (3.7 g-L"') in 75 mL plastic bottles (Costar, MA, USA) at 37 °C, 
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under 7.5% CO2. Antibodies to IL-2 (HB 8794), IL-2 receptors (CRL 1698 
and TIB 222), IA" (MKD6), Mac 2 (TIB 166), L3T4 (GK1.5), Lyt 2.2 (TIB 
210) and IL-4 (1 IBl 1) were used as culture supernatants of the hybridomas. 
The P815 cells, an MHC matched (H-2*') mastocytoma cell line; EL-4 cells, 
an MHC disparate (H-2''^ lymphoma cell line and hybridomas used in the 
study were procured from ATCC (Rockville, MD). [^H]-thymidine and 
[^'Cr] sodium-chromate were bought from Bhabha Atomic Research Center, 
Mumbai, India. 
Isolation and purification of egg Phosphatidylcholine (egg PC) 
Egg PC was isolated and purified following the published procedure 
(Singleton et al, 1965). Briefly, egg yolks of one dozen eggs were separated 
carefully, and washed with acetone (100 ml) in a mixer 5-6 times to get rid 
off the colored impurities. The resulting white solid was powdered and 
dried in vacuum for 2 hr to remove traces of the solvent. The extraction was 
performed by stirring the solid mass with one liter of absolute alcohol for 2-
3 hours. After filtration, the residue was re-extracted with another 500 ml of 
ethanol. t h e filtrates were mixed and evaporated off at 40-45 °C. The sticky 
mass thus obtained was dried under high vacuum to remove traces of the 
solvent, dissolved in minimum amount of petroleum ether (b.p.60-80 °C) 
and poured onto chilled acetone to obtain a white sticky precipitate. The 
solvent from the precipitated material was removed by decantation. The 
sticky solid precipitate was redissolved in petroleum ether and again poured 
onto the chilled acetone. The process was repeated 2-3 times to obtain crude 
PC. For further purification, it was chromatographed on a neutral alumina 
(grade III) column. The elution was performed using increasing amount of 
methanol in chloroform. Fractions obtained with 5-7 % methanol in 
chloroform corresponded to pure PC. It was further purified by 
chromatography over Sephadex LH-20 colurhn (2.5x 100 cm), using 
chloroform/methanol (1:1 v/v) as the eluant. The elution rate was 
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maintained at 60-70 ml per hour. Fractions were collected and checked for 
the presence of pure PC. The purity was ascertained by thin layer 
chromatography using silica gel G-60 TLC plates. The plates were 
developed using chloroform/methanol/water (65:25:4) as the solvent system, 
and stained with iodine vapour followed by molybdenum-blue spray to 
visualize various phospholipid spots. 
E. co// lipids 
E. coli K12 strain (non-pathogenic) was kind gift from Mr. Zeeshan 
Ansari, Nil, New Delhi. E. coli K12 was cultured in nutrient broth (1% 
peptone, 0.3% beef extract, 0.3% yeast extract and 1% sodium chloride; pH 
7.4). The cells were harvested from mid-log phase (18-20 h). Phospholipids 
were isolated by the method of Bligh-Dyer, as modified by Kumar & Gupta 
(Kumar & Gupta 1983). Briefly, one gram of cell pellet was sonicated in 
50ml methanol for one hour at 4°C in bath type sonicator. To the cell 
suspension two volumes of chloroform was added and kept on stirrer 
overnight. The solution was then filtered through Whatmann filter paper to 
remove cell debris. The filterate was then fractionated three times with one-
fifth volume of normal saline to remove protein content. The solution was 
finally evaporated in round bottomed flask with suitable azeotrope in rotary 
evaporator. The lipid composition was determined as described previously 
and found to be as follows: phosphatidylethanolamine, 82 ± 1.2; 
phosphatidylglycerol, 13.8 ± 0.8; cardiolipin, 4.2 ± 0.6. 
Preparation of liposomes (Dehydration-Rehydration Vesicles) 
Dried reconstituted vesicles (DRVs) were prepared using published 
method (Kirby & Gregoriadis 1994). Briefly, egg PC/cholesterol (2:1 molar 
ratio, total 20 mg) or E. coli lipids (20 mg) were reduced to thin dry film 
under N2 atmosphere. The film was hydrated, followed by sonication in a 
bath-type sonicator for 2 h at 4°C under N2 atmosphere. The liposomes thus 
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formed were mixed at this stage with an equal volume of OVA (30 mg/ml). 
The mixture was flash frozen and thawed (3 cycles), and then lyophilized. 
The free-flowing, dried powder thus obtained was rehydrated with distilled 
water (120 |il) and finally re-constituted with PBS. The preparation was 
centrifuged at 14,000 x g and the pellet was further washed at least 3 times 
with PBS to remove the traces of the unentrapped solute. The protein 
entrapped in the liposomes was estimated by BCA method (Smith et. al. 
1985). Briefly, the liposomes (given volume) were lysed with 10% Triton 
X-100 solution (the final concentration of Triton X-100 was maintained 
1%). The mixture of solutions A and B of BCA reagent was added to the 
lysed liposomes (released protein) and then incubated at 37 °C for 45 min. 
The absorbance was measured at 570 nm and the protein concentration was 
calculated using a standard curve of OVA plotted in the presence of Triton 
X-100. 
Immunization 
The immunological studies were performed in inbred female Balb/c 
mice. Each group was consisted of five animals. The animals were 
immunised with various preparations (Free OVA or OVA entrapped in 
liposomes) of antigen on various days. The immunization schedules adapted 
for administration of OVA into the animals varied from experiment to 
experiment depending upon nature of the study, and described accordingly. 
Cell preparation 
(a) CD8^ T cells 
Different groups of Balb/c mice were injected separately, through 
intravenous route, with a total three doses (day 0, 7, and 14) of free-OVA, 
OVA encapsulated in egg PC/chol or E. coli lipid liposomes and also with 
free ovalbumin mixed with empty liposomes [100 /ag OVA (which 
correspond to 500 nmoles of lipid)/animal/week] for 3 weeks. On day 21, 
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the animals (five animals each group) were sacrificed and spleens were 
taken out aseptically. The cells were prepared as described elsewhere 
(Mitchell & Shiigi 1980). The cells obtained from different animals in a 
given group were pooled, purified and used in cyto-toxicity assay. The 
enriched population stained with anti-CD8 Ab, was >98% pure, as evaluated 
by FACScan. 
(b) CD4* T cells. 
Animals were immunized either with single dose of free OVA, OVA 
encapsulated in egg PC/chol or E. co//-lipid liposomes (100 |ig 
OVA/animal) through intra-venous route. On day 7, the animals (five 
animals each group) were sacrificed and their spleens were removed 
aseptically and €04"^ T cells were isolated as described elsewhere (Mitchell 
& Shiigi 1980). For lymphokine assay experiments, the animals were 
immunised intravenously using two different immunising schedules. In one 
set, the animals (five animals each group) were immunised with single dose 
of OVA (100 |ig OVA/animal), while in another set, the animal were 
immunised with total three doses of OVA (100 ^g OVA per animal, on day 
0, 7, and 14). On day 21, the animals were sacrificed and CD4^ T cells were 
isolated as described above. The enriched population of 004"*" T cells were 
stained with anti-CD4 and anti-CD3 Abs and the purity was found to be 
>98%, as revealed by FACScan. 
ODZ" T lymphocyte response. 
(a) Target cells 
Balb/c mice were injected with thioglycollate broth. On day 4, the 
macrophages were isolated from the PEC by adherence on Petri plates. The 
harvested cells (2xl0'cells/ml) were washed. 3 times with HBSS and 
incubated at 37 "C for 3-4 h with either free OVA, OVA entrapped in egg 
PC/chol or encapsulated in escheriosomes. The cells were again washed 3x 
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to remove free antigen. This was followed by incubation with ^'Cr (100 
nCi/2xlO' cells) for 45-60 min at 37 °C. The cells were finally washed with 
RPMI solution and were used as target cells. 
(b) Cytotoxicity assay. 
The ^'Cr-labelled macrophages/P815 cells (SxloVwell) were used as 
target cells. The antigen primed target cells were incubated with CD8* T 
cells (effector cells isolated from the spleen of the five mice were pooled, 
and used for assay) at an effector to target (E/T) ratios of 2.5:1-20:1. The 
ceils were incubated at 37 °C for 6 h, after completion of incubation period, 
the cells were pelleted at 3000 x g (15 min, 5 "C) and the amount of ^'Cr 
released was determined by measuring the radioactivity in the supernatant. 
The experiments were performed three times and the error bars represent 
standard deviation of the means from three different experiments. Total "Cr 
release was calculated by treating an aliquot of the target cells with Triton 
X-100 (10% final concentration). The spontaneous release of ^'Cr in the 
supernatant was determined by incubating the labeled macrophages for 6 h. 
Amount of auto-release was subtracted from the total release to determine 
the extent of macrophage lysis. In most of the experiments, the auto-release 
was less than 25%, The percent specific release was calculated as the (mean 
sample cpm-mean spontaneous cpm/mean maximum cpm-mean spontaneous 
cpm) X 100%. 
C04 T cell proliferation. 
The 004"^ T cells (2xl04/well) obtained from pool of the splenic 
cells of five mice from different groups, were cultured in triplicate wells. 
The cells were incubated with macrophages (6xl0^/well) pulsed with 
different doses (0.001-100 |ig/ml) of free OVA or encapsulated in egg 
PC/chol or E. coli lipid liposomes. The macrophages were treated with 
mitomycin C (50 ^g/ml). The cultures were incubated for 72 h at 37 °C/7% 
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CO2. The cells were pulsed with 1.0 |iCi [^H]-thymidine for 16 h before 
harvesting with an automatic cell harvester (Skatron, Tranby, Norway). The 
[^H]-thymidine incorporation was measured by a standard liquid 
scintillation counting method. The results are expressed as mean cpm of 
triplicate cultures. 
Lymphokine assays. 
The cultures were set up as described for T cell proliferation. The 
supernatants were collected after 48 h for estimation of IL-2, IL-4 and IFN-
Y levels. The IL-2 and IL-4 were assayed using the HT-2 cell line, while 
IFN-y was estimated by its ability to inhibit the proliferation of WEHI-279 
cells (Agrewala et. al. 1998). The lymphokines data were expressed as 
pg/ml in the culture supernatants as computed by comparison with the 
standard curve plotted, using r IL-2/rIL-4 and rlFN-y (Genzyme, USA). 
Determination of OVA-speclfic igG isotypes by ELISA. 
The production of OVA specific antibodies was measured in the sera 
of the immunized mice. The animals were injected, intravenously, with two 
doses of free OVA, OVA entrapped in the egg PC/chol or E.coli lipid 
liposomes (100 ng OVA/animal) on day 0 and 7, and bled on day 14 to 
monitor the presence of antibodies as described earlier (Agrewala et. al. 
1998). Briefly, ninety-six well microtitre plate was incubated overnight 
with 50 |il of OVA (25 p,g/ml) in carbonate-bicarbonate buffer (0.05 M, pH 
9.6) at 4 °C. After usual washing and blocking steps the plate was finally 
incubated with 1:500 dilutions of test and control sera at 37°C for 2h. After 
excessive washing of the plate, it was further incubated with 50 |il of 
biotinylated goat anti mouse IgGl and IgG2a antibodies. The plate was 
incubated at 37**C for Ih. After the usual washing steps, 50 \i\ of 
streptavidin-HRP were added to each well and the plate was incubated at 37 
°C for Ih. The plate was washed again before adding 50 i^l ABTS and was 
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finally incubated at 37°C for 20 min. The reaction was terminated by the 
addition of 50 y\ of 70% H2SO4. The absorbance was read at 492 nm with a 
microtitre plate reader (Eurogenetics, Torino, Italy). 
Statistical Analysis 
The data were analysed by one-way analysis of variance (ANOVA) 
following Dunnet's t test method. P < 0.05 was considered statistically 
significant. 
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1. Delivery of the antigen entrapped in the fusogenic E. coli lipid 
liposomes elicits effective cytotoxic T cell (CTL) response. 
Keeping into consideration the fact that escheriosomes possess a 
strong fusogenic character, in principle such liposomes should deliver the 
entrapped protein into the cytosol of the APCs for presentation via MHC 
class I pathway. We evaluated the potential of escheriosomes entrapped 
OVA, to undergo MHC-I processing and presentation to generate a CDS"^  T 
cell response. Initially, animals were immunized with varying doses of 
antigen entrapped in escheriosomes (10-100 |ig OVA/per dose/per animal, 
total three doses each at week interval). It was found that a dose of 100 jig 
per animal induced CTL response, which generated 30-40 % target lysis at 
an effector to target ratio of 20:1 (data not shown). This dose was selected 
for subsequent studies performed for ^'Cr release assay. Interestingly, 
immunisation with OVA entrapped in the escheriosomes, but not other forms 
of OVA viz. free-OVA or OVA entrapped in egg PC/chol liposomes and free 
OVA mixed with empty escheriosomes (sham liposomes), generated 
cytotoxic T cells. A considerably high degree (30-40%) of target cell lysis 
occurred when the OVA was encapsulated in the escheriosomes, as 
compared to less than 1% specific lysis in free-OVA or OVA incorporated 
into the egg PC/chol liposomes or sham escheriosomes (Fig. 3). Further the 
results of Fig. 4 demonstrated that, beside P815 cells, escheriosomes 
induced effector cells can recognize other target cells with equal propensity. 
We incubated thioglycoUate-elicited macrophages with various liposomal 
forms of OVA and used them as target cells to perform cytotoxity assay. The 
result of the present study clearly demonstrates that target cells primed with 
escheriosomes encapsulated OVA were recognized by effector cells, while 
other forms of OVA (free or egg PC encapsulated) failed to do so. 
63 
^Atj^/iBtt /.- crteuUti 
Figure 3: Induction of antigen specific CTL activity by 
immunisation with escherioso/nes containing various 
forms of ovalbumin. 
The Balb/c mice were immunised with ( ) saline, (•) Sham escheriosomes 
(Sham EL), ( • ) Free OVA, ( • ) escheriosomes mixed with OVA (EL + 
OVA), ( T ) OVA encapsulated in Egg PC liposomes (PC-OVA) and ( • ) 
OVA encapsulated in escheriosomes (EL-OVA), as described in materials 
and methods. The effector cells were isolated from spleen of five mice, 
belonging to various groups mentioned as above. The cells were pooled, 
purified and used for target cell lysis assay. The target cells (P 815) were 
pulsed with saline. Sham EL, Free OVA, escheriosomes mixed with OVA 
(EL + OVA), OVA encapsulated in Egg PC liposomes (PC-OVA) and OVA 
encapsulated in escheriosomes (EL-OVA) respectively (30 ^g OVA/ 2 x 1 0 ^ 
cells), and labelled with Cr. Lytic activity was measured by incubation of 
suitable effector cells with target cells (primed with matching formulation of 
OVA). The results are represented as, percent specific lysis (^'Cr release) of 
the target cells. Each value represents the mean of three determinations ± 
S.D. Data are representative of five independent experiments performed with 
similar results, (p value <0.001) 
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Fig. 4: OVA specific effector cells can recognize 
macrophages as target cells. 
The Balb/c mice were immunised with (f t ) Saline, ( • ) Free OVA, ( • ) 
escheriosomes mixed with OVA (EL + OVA), ( • ) OVA encapsulated in Egg 
PC liposomes (PC-OVA) and (A) OVA encapsulated in escheriosomes (EL-
OVA), as described in materials and methods. The effector cells were 
isolated from spleen of five mice, belonging to various groups mentioned as 
above. The cells were pooled, purified and used for target cell lysis assay. 
The thioglycoUate elicited macrophages (target cells) were pulsed with Free 
OVA, escheriosomes mixed with OVA (EL + OVA), OVA encapsulated in 
Egg PC liposomes (PC-OVA) and OVA encapsulated in escheriosomes (EL-
OVA) respectively (30 i^g OVA/ 2 x lO' cells), and labelled with ^'Cr. Lytic 
activity was measured by incubation of suitable effector cells with target 
cells (primed with matching formulation of OVA). The results are 
represented as, percent specific lysis (^'Cr release) of the target cells. In the 
case of control wells, target cells incubated with effector cells (OVA 
reactive CD8^ T cells) in the absence of antigen or with sham liposomes (no 
antigen) and unrelated antigen (lysozyme entrapped in escheriosomes), there 
was not more than 2% of ^'Cr-release. Each value represents mean of three 
determinations ± S.D. The experiment was performed four times with 
similar results. 
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Results shown in Fig. 5 confirm the phenotype of the effector cells. 
The pre-treatment of the purified effector cells with anti-CDS"^ antibodies, 
followed by treatment with baby rabbit complement, abolished target cell 
lysis. We further demonstrated that P 815 cells, primed with free or egg PC 
liposomes encapsulated OVA, couldn't act as target cells (Fig. 6). The 
effector cells, obtained from the animals immunised with escheriosomes, 
were allowed to incubate with the target cells, which were primed with 
different liposomal forms of OVA, i.e. free OVA, OVA encapsulated either 
in egg PC liposomes or escheriosomes. The ^'Cr release assay shows that 
OVA specific CTLs successfully distinguished the target cells, which were 
incubated with escheriosomes for antigen presentation, however, egg PC 
liposomes pulsed target cells were not recognized by the same CTLs 
(P<0.001). Moreover, the recognition of target cells is confined to the MHC 
compatible cells only, thus effector cells were able to induce lysis of P 815 
cells, while allogenic EL-4 cells (H-2'') were not recognized at all by the 
same effector cells (Fig. 6). 
CD4* T cell response. 
(a) Antigen entrapped in tlie E.coli-lipid liposomes enliances 
CD4^ T cells proliferation. 
In the present study, we analyzed the stimulatory potential of various 
forms of OVA on the proliferation of antigen specific T cells. T 
lymphocytes obtained from mice immunized with antigen encapsulated in 
the escheriosomes induced significantly higher proliferation as compared to 
the T lymphocytes obtained from animals immunized with egg PC/chol 
liposomes (Fig 7). T-cell responsiveness to antigen was observed in a dose 
dependent manner. Control cultures containing cells obtained from either 
OVA immunized animals or the groups immunized with PBS or fusogenic 
lipids only (sham liposomes with no OVA), gave background levels of 
<2000 cpm of •'H-thymidine incorporation. 
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F ig . 5: OVA encapsulated in Escheriosomes can induce T 
lymphocytes with CDS* phenotype. 
Effector cells obtained from the OVA (encapsulated in escheriosomes) primed 
animals were pre-treated with anti-CD4^ or anti-CD8^ monoclonal antibodies 
followed by incubation with baby rabbit complement. The effector cells were 
incubated with OVA pulsed, ^'Cr loaded target cells. The lysis of the target 
cells was measured by ^'Cr release assay. (•) anti-CD8* antibody pretreatment, 
(•) anti-CD4"^ antibody pretreatment, ( T ) pretreatment with complement 
alone, ( ) No pre-treatment. Values are mean of three determinations ± S.D. 
Data are representative of five different experiments with similar results. 
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Fig. 6: Escheriosomes provide an efficient means of 
sensitising target cells to class I restricted CTL 
recognition. 
Balb/c mice were immunised with ovalbumin encapsulated in escheriosomes. 
Cytotoxic T cells isolated from the spleen of ten mice were pooled, and used 
as effector cells for cytotoxic assay. The MHC restriction as well as antigen 
specificity of the generated CTLs was demonstrated by ^'Cr release assay. 
The target cells, P815 (H-l") were pulsed with various forms of ovalbumin 
viz free OVA (o), ovalbumin encapsulated in egg PC liposomes ( • ) , 
ovalbumin encapsulated in escheriosomes (V) and incubated with effector 
cells, isolated from EL-OVA treated animals at varying effector to target cell 
ratio (2.5:1 to 20:1). In another set, target cells, EL-4 (H-2'')) were incubated 
with escheriosome encapsulated ovalbumin and incubated with same effector 
cells ( • ) . The lysis of the target cells was measured by ' 'Cr release assay. 
Data are mean of three determinations ± S.D. 
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Fig 7: Antigen Incorporated in Escheriosomes augmented 
the proliferation of OVA-specific Tti cells. 
CD4^ T cells (2xl0Vwell) were isolated from the groups of 5 animals 
immunised with OVA encapsulated either in E.coli-lipid liposomes (EL-
OVA) or egg-PC/chol liposomes (PC-OVA) and cultured with the OVA, EL-
OVA and PC-OVA pulsed macrophages (6xl0'*cells/well). After 72h, [^H]-
thymidine was added, and its incorporation was measured 16h later by liquid 
scintillation spectroscopy. The control cultures consisting of Th 
cells+medium (no OVA), macrophages+medium, Th cells + E.coli-lipid 
sham liposomes (no OVA), medium+Th cells obtained from the animals 
immunised with placebo (PBS) showed <2000 cpm. The data represents 
mean cpm of three determinations ± S.D. The experiment was repeated four 
times with similar results. 
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(b) Antigen encapsulated Into E.coli-lipid liposomes enhances the 
production of IL-2, IL-4 and IFN-y. 
The animals immunised with single dose of antigen encapsulated in 
the escheriosomes as well as egg PC/chol liposomes showed only marginal 
secretions of IL-2 (14.4 pg/ml and 8 pg/ml respectively). However 
significant enhanced level of IL-2 was found in animals boosted three times 
with escheriosomes encapsulated antigen (139pg/ml) as compared to egg PC 
liposomes (28pg/ml) boosted animals (Fig 8). 
In contrast the animals immunized with single dose of escheriosomes 
encapsulated antigen showed significantly low level of IL-4 (220pg/ml) as 
compared to egg PC/chol liposomes (365pg/ml). However the level was 
enhanced in escheriosomes immunized animals (490pg/ml) as compared to 
PC-OVA (415pg/ml) after three boosters (Fig 9). 
The animals immunised with single dose of antigen encapsulated in 
the escheriosomes as well as egg PC/chol liposomes showed only marginal 
secretions of IFN-y (20 pg/ml and 16 pg/ml respectively). However 
significant enhanced level of IFN-y was found in animals boosted three 
times with escheriosomes encapsulated antigen (88.4 pg/ml) as compared to 
egg PC liposomes (29.2 pg/ml) boosted animals (Fig 10). 
No detectable amount of lymphokines was observed in the case of 
control animals inoculated either with PBS, sham egg PC/chol or E. coli-
lipid-liposomes alone (no antigen). 
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F i g . 8. OVA loaded liposomes prepared from fusogenic lipids 
of E.coli enhances IL'2 level. 
The cultures were set as mentioned in the legend to Fig. 7. The lL-2 content 
in culture SN was measured by its ability to induce the proliferation of HT-2 
cells. The cells were incubated in 96 well plate (IxlO^'/well) in the presence 
of culture SNs (treated with anti lL-4 antibody [ l l B l l , 1 |ig/ml] to block 
IL-4), for 16 h at 37 °C, pulsed with 0.5 ^Ci [3H]-thymidine and harvested 8 
h later. The thymidine incorporation was measured by liquid scintillation 
spectrometry. The IL-2 content was computed from standard plot of rIL-2, 
and expressed as pg/ml. Data are representative of three different 
experiments performed with similar results. 
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F i g . 9 . 0W\ loaded liposomes prepared from fusogenic lipids 
of E.coli enhances IL-4 level. 
IL-4 content was determined using same method as that of IL-2, except here, 
IL-4 was neutralised by anti-IL-4 mAb (cocktail of 1:12 dilution of culture 
SN of CRL 1698, HB 8794 and TIB 222). The proliferation of HT-2 was 
assayed in similar manner and data were computed with the standard plot of 
rIL-4. All data were calculated from the mean cpm of triplicate observations 
and expressed as pg/ml ± S.D., after back calculation.. The data are 
computed in manner similar to that of IL-2, and represented as mean of 
triplicate observations ± S.D. Data are representative of three different 
experiments performed with similar results. 
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F i g . 1 0 . 0\AA loaded liposomes prepared from fusogenic lipids 
of E.coli enhances IFN-Y level. 
The secretion of IFN-y was measured by its ability to inhibit the 
proliferation of WEHI-279 cells. The IFN-y content was computed from 
standard plot of rlFN-y, and expressed as pg/ml. Data are representative of 
three different experiments performed with similar results. 
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Humoral Immune response 
The significant high titre of antibodies was detected in sera of the animals, 
which were primed with OVA entrapped in the escheriosomes as compared 
to the animals, inoculated with egg PC/chol liposomes (Fig 11). However, 
mainly IgGl antibodies were generated in both the cases, while IgG2a type 
of antibody were induced to lesser extent only (P<0.05). No IgGl and 
IgG2a-isotypes were detected in the control group of mice injected with 
either sham Escheriosomes/egg PC/chol liposomes (no antigen) or PBS. 
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F i g . 1 1 . Escheriosomes increase the secretion of antigen 
specific IgG isotype. 
The Balb/c animals were immunised with different preparations of OVA as 
described in materials and methods. Sera (1:500 dilution) obtained from the 
control and experimental animals were analysed for the presence of OVA-
specific IgG-isotype by ELISA method as described in materials and 
methods. The levels of the two major isotypes of the IgGs were expressed as 
absorbance (A492) of the coloured complex developed in the immunosorbent 
assay. The values expressed are the mean of the absorbance of the sera of 
five different animals ± S.D. The control animals immunised with PBS, free 
OVA or sham liposomes (no antigen), could not induce any detectable level 
of IgG-isotype. 
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Protective immunity against intracellular bacteria (tuberculosis, 
leprosy), fungi (cryptococcosis, candidiasis), protozoans (leishmaniasis, 
malaria), viruses and cancer requires active involvement of the pathogen 
specific CD8^ T lymphocytes (Liebna et. a/. ,1999,Nickell 1993,Muller et. 
al. 1991,Deres et. al. 1989,Malik et. al. 1993,Sasiain et. al. 1998). 
Ironically, prevalent immunization protocols result in the development of 
humoral immune response mainly; on the contrary generation of cytotoxic T 
cells always remains a major uphill task (Audibert & Lise 1993,Leclerc & 
Ronco 1998). Moreover, some of the presently available antigen delivery 
systems viz. virosomes, pH sensitive liposomes or fusogenic protein bearing 
liposomes, which are claimed to induce strong immunogenic responses 
against entrapped antigen, can not be recommended because of cost factor, 
toxicity as well as structural components (c/ protein and carbohydrate) 
induced immunological complications (Mandal & Lee 2002, Polt-Frank et. 
al. 1999, Lee et. al. 2002,Kunisawa et. al. 2001, Babai et. al. 2002, Harding 
et. al. 1991). The present study offers a novel method of activating both the 
arms of immune system and suggest that escheriosomes based delivery 
systems successfully activate host immune system for the generation of 
antigen specific antibody as well as T lymphocyte responses. 
Previously, several groups have demonstrated that liposomised 
antigens are avidly taken up by the antigen presenting cells, and lead to the 
production of IL-4 mainly (Agrewala et. al. 1996). Thus in spite of the 
adjuvant effect of liposomes in terms of increased humoral immunity, it 
miserably fails to activate the cell-mediated immunity. To meet demand of 
the ordeal, I evaluated escheriosomes for their ability to breach cell 
membrane barrier and deliver entrapped solutes in the cytosol of the of the 
target cells including macrophages. Keeping in consideration the potential of 
escheriosomes to deliver their contents in to cytosol of the antigen 
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presenting cells, it is tempting to study their potential to induce antigen 
specific cell mediated immunity. 
The following four major findings have emerged from the present 
study:-
i) The escheriosomes effectively deliver their contents (antigens) 
into class I and class II antigen processing pathways; 
ii) effector CDS'" cytotoxic T cells were stimulated (Fig 3,4,5,6); 
iii) CD4"^  T-helper cells, predominantly of Th2 phenotype were 
generated (Fig 7, 9); 
iv) predominant secretion of IgGl-isotype was observed (Fig. 11). 
It is evident from present study that immunogenicity of ovalbumin is 
controlled by nature of adjuvant/antigen carrier used for immunization (Fig. 
3). The antigen entrapped in escheriosomes elicits antigen specific CTL 
generation, while other forms of antigen e.g. OVA entrapped in egg PC 
liposomes fail to generate CTL. Further, the processing and presentation of 
antigen depends on its mode of delivery, as CTLs obtained from animals 
immunized with escheriosomes-OVA, can induce lysis of target cells which 
were, in vitro, primed with same liposomal preparation. The same effector 
cells do not lyse target cells, which were, in vitro, primed with egg PC 
liposomes or free ovalbumin (Fig. 6). These experiments clearly show that 
target cells primed with OVA encapsulated in egg PC liposomes can not be 
recognized by effector cells i.e. OVA specific CTLs isolated from mice 
immunized with OVA encapsulated in escheriosomes. The results of the 
present study also demonstrate MHC restricted lysis of the target cells, as 
MHC mismatched allogenic targets (EL-4 cells) were not identified by same 
effector cells. We also established that the CTL response was antigen 
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specific, as target cells primed with lysozyme (an unrelated antigen) were 
not recognized by the OVA specific CTLs (Fig. 6). 
To demonstrate that antigen specific effector cells are effectively 
recognizing naturally occurring antigen presenting cells as well, we 
replaced P 815 cells with thioglycollate elicited macrophages to perform 
CTL assay. We found that antigen primed macrophages, in manner similar to 
P815 cell, can be specifically lysed by the OVA specific effector cells (Fig. 
2). Phenotype confirmation of the effector cells was performed by pre-
treatment of the cells with anti CDS"^  antibodies, before using them for ^'Cr 
release assay. The result shows that such pre-treatment abolishes CTL 
response, which confirms the CDS"^  phenotype of the generated T 
lymphocytes (Fig. 5). 
The results of the present study further demonstrate that egg PC 
liposomes interact with APCs by endocytic mode mainly resulting in the 
induction of 004"*^  T cell response (Braciale et. al. 1987, Lee et. al. 2002, 
Harding et. al. 1991). In contrast, the escheriosomes appear to interact with 
the target cells by both endocytosis as well as membrane fusion mode, thus 
helping in the activation of both 004"^ T-helper as well as CD8* cytotoxic T 
cells. It is important to mention here that the CD4 T cell proliferation 
responses generated using the escheriosomes were better than those 
observed with the egg PC liposomes. 
A fine orchestration is needed between CD4 T cell and CD8 T cell 
responses for an effective control of the intracellular parasitic infections. 
Various lines of evidences suggest that in addition to helper T cells 
(required for activation of macrophages), it is primarily the cytotoxic T 
cells, which play crucial role in the protection. It is evident from situations 
when in spite of optimum level of CD4'*^  T cell response, the disease 
develops to progression in the absence of CTL cells (Flynn et. al. 
1992,Tarleton et. al. 1992). Thus encapsulation of the protective antigens in 
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the escheriosomes is likely to elicit strong CTL-response necessary for 
protection against intracellular infections. 
In addition, the use of escheriosomes also leads to the generation of 
CD4^ Th2 type of cells. These cells provide help to B cells leading to the 
production of antibodies, while Thl cells are crucial for the activation of the 
CTLs (Stevens et. al. 1988, Shaji et. al. 1998). The Thl/Th2 shift is crucial 
to the effective immunity and it is likely that many interlocking factors will 
contribute to that decision (Bottomly 1988). Although the expression of Thl 
type and Th2 type cytokines was initially considered to be mutually 
exclusive, T helper cell expressing both Thl and Th2 cytokines {cf, ThO) 
have been identified both during differentiation of Th cells and in terminally 
differentiated cells (Bottomly 1988). The escheriosomes mediated strong 
CTL generation, in spite of the observed polarization of the CD4 T cell 
response in favor of Th2 cells, can be attributed to the physical targeting of 
the entrapped antigen to the cytosol of the antigen presenting cells. The 
escheriosomes like other particulate substances are avidly endocytosed by 
APCs and activate CD4 T cell. However, it cannot be excluded that in 
addition to endocytosis, a substantial portion of the entrapped antigen is 
delivered to the cytosol of the target cells, and form the basis of the 
observed antigen specific CTL response. Recently, Gerosa et. al. have 
demonstrated that genes for both class of cytokines are independently 
regulated and that any combination of them can be observed without a clear 
distinction along the Thl or Th2 phenotype (Gerosa et. al. 1996). Since it is 
well established fact that both CTLs and the neutralising antibodies are 
essential for imparting protective immunity against such pathogens hence 
the peculiar behavior of the escheriosomes-based delivery system, in a way 
could be more desirable feature in activation of both cell mediated as well as 
humoral immune responses, a vaccination strategy for elimination of viruses 
and intracellular parasitic infections. (Flyn et.al. 1992, Tarleton et. al.1992, 
Siegrist et.al. 1999, Mo et. al. 1997). 
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One can argue that beside lipid some other structural components can 
be considered as possible factor responsible for observed immunological 
manifestations. This can be ruled out on the premise that no protein or 
carbohydrate residues were found to be present in escheriosomes as revealed 
by their chemical analysis. This was further confirmed by SDS/PAGE, 
which was found negative for any protein content upon silver staining 
(Ahmad e/. al. 2001). Finally, the observations made in the present study 
that both sham escheriosomes as well as physical mixture of antigen and 
preformed escheriosomes failed to activate T lymphocytes clearly support 
the notion that it is fusogenic properties of the escheriosome based delivery 
system that help in elicitation of immunological responses (Fig. 3, Fig. 7). 
In spite of the fact that E. coli resides as commensal and constitutes a 
major component of gut flora, it is premature to rule out presence of toxic 
components in the lipid isolated from it without performing chronic toxicity 
test. However, our preliminary studies demonstrated no phlebitis like 
symptoms at the site of injection or general discomfort upon its 
administration in the immunized animals. Beside, exposure of P 815 cells (1 
x 10^ cells/well) with escheriosomes (2ng lipid P//well) did not inflict any 
toxicity to the cells as revealed by MTT- micro culture tetrazolium assay 
(data not shown). Finally, the safety of escheriosome can be further 
established by the fact that its incubation with antigen presenting cells did 
not hamper their physiological activities and they successfully process 
antigen to express them with appropriate major histocompatibility 
complexes. 
Recently, fusogenic potential of yeast lipid liposomes have been 
established and found that immunization with antigen encapsulated in such 
liposomes can successfully activate both humoral as well as cell mediated 
immune responses (Owais et. al. 2001). Although, both yeast lipid liposomes 
as well as escheriosomes based antigen delivery systems elicit strong 
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immunological responses, however, later may offer several advantages for 
its possible use as antigen carrier. In fact less heterogeneous composition of 
E. coli lipid is likely to impart less toxicity risk as compared to the complex 
phospholipid profile of yeast membrane lipid. Beside, the less generation 
time of E. coli {cf. 20 min) as compared to yeast (c/. 2 h) will certainly be 
advantageous in harvesting larger amount of the microbe in less time period 
and would be more economical when used for bulk isolation of lipid. 
Moreover, the presence of two-membrane system as well as small size of the 
E. coli yields at least 4-5 times higher amount of lipid when isolated from 
same biomass of yeast cells (personal observation). 
It may be inferred from the study that due to strong fusogenic 
character of lipids, escheriosomes can effectively deliver antigen to both 
class I and class II processing compartments of antigen presenting cells, thus 
generating a strong antigen-specific CD8^ (cytotoxic) and CD4"^  (helper) T 
cells simultaneously. Such considerations, which could selectively enhance 
CTL and T-helper cells are pertinent in designing liposomes based vaccines, 
and hence will subserve in protection against the infectious diseases. 
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'::;:monella typhimurium (S. typhimurium) is a gram-negative, rod 
shaped, motile bacterium classified as a member of family enterobacteriacie, 
grouped under order enterobacteriales. It is a facultative intracellular 
pathogen causing self-limiting gastroenteritis in humans and typhoid like 
systemic disease in mice (Finlay 1994, CDC, 1982.). There is widespread 
occurrence of bacterium in animals, especially in poultry and swine. 
Environmental source of the organism include water, soil, insects, factory 
surfaces, kitchen surfaces, animal faeces, raw meat, raw poultry, and raw sea 
foods to name a few. Pathogenic Salmonellae ingested in food survive 
passage through gastric acid barrier and invade the mucosa of small and 
large intestine and produce toxins. Invasion of epithelial cells stimulate the 
release of proinflammatory cytokines, which induce an inflammatory 
reaction (Finlay 1994, CDC, 1982.). The acute inflammatory response 
causes diarrhea and may lead to ulceration and destruction of the mucosa. 
The bacteria can disseminate from intestines to cause systemic disease in the 
host. Like most of the other intracellular pathogens. Salmonella has also 
developed means to evade professional phagocytes {cf. macrophages) by 
relying on intracellular parasitism as strategy to survive the immune 
onslaught (CDC, 1982). Salmonella survives and replicates inside 
macrophages (Fields, et al.l986) and remain confined inside the vacuole (Oh 
et.al 1996). It has evolved series of strategies to survive inside the harsh 
milieu of the phagosomal compartment. Delay in acidification of 
phagosomes, tolerance to acid stress and resistance to family of 
antimicrobial peptides called defensins are some of the means of adaptation 
used by S. typhimurium (Foster and Spector 1995). In addition, by itself it is 
cytotoxic for phagocytosing cells (Lindgren and Heffron 1997). Mutants of 
S. typhimurium that cannot survive within macrophages are avirulent (Fields 
et. al. 1986). Invasive S. typhimurium onslaught induces dramatic changes in 
membrane surface of macrophages as part of their entry mechanism, which 
leads to the apoptosis of the host cells. The ability of Salmonella to promote 
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;,poptosis may be important for initiation of infection, bacterial survival and 
r/.cape of host immune response (Monack et. al. 1996). 
The recent emergence of multidrug resistant Salmonella strain call for 
more rational approach for its medical treatment on one hand, and increase 
the urgency for rapid development of safe and more effective vaccine on the 
other (Izumiya et. a/.2001, Blanden et. al. 1986.)- This requires better 
understanding of protection mechanism acquired by Salmonella that would in 
turn help in improving the chemotherapeutic approaches as well as 
vaccination strategies. Development of effective vaccine against intracellular 
pathogen has always been a challenge as it requires an immunization 
protocol that can activate both arms of immune system (humoral as well as 
cell-mediated) for successful elimination of pathogen. Numerous studies 
have demonstrated that humans as well as experimental animals respond to 
salmonella infection by activating both humoral as well as cell mediated 
immune responses (Hess & Kauffman 1997, Jones & Falkow 1996). The 
activation of primary immunity often takes longer than bacterial growth. 
Hence, the development of protective immunity through vaccination could be 
of great significance. 
Considerable literatures have documented the potential of liposomes 
as antigen carriers, however antigenic depot provided by liposomes leads 
only to MHC class II presentation of processed antigens which ultimately 
ensues activation of humoral immune response mainly (Alving et. al. 1992, 
Agrewala et. al. 1996). In contrast, soluble antigen that is delivered into 
cytosol of antigen presenting cells for processing is normally presented along 
with MHC-1 molecule forms the basis for induction of CTL response. This 
clearly suggest that antigen delivery vehicles successful in introducing the 
entrapped immunogenic antigens to the cytosol of the antigen presenting 
cells may offer protective immunity against intracellular pathogen like S 
typhimurium. In this regard fusogenic liposomes have attracted much greater 
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attention as they fulfill criteria to facilitate activation of CTLs and thus holds 
a great deal of promise in vaccine development (Reddy et. a/. 1991, Polt 
Frank et.al 1999). 
Aim of the present work 
After establishing the fact that escheriosomes are better adjuvant as 
they have got potential to activate both humoral and cell mediated branch of 
immune system, in the next part of study we have exploited escheriosome as 
vaccine adjuvant against experimental murine salmonellosis. The in vivo 
administration of escheriosomes encapsulated cytosolic antigen of S. 
typhimurium (EL-Ag) was demonstrated to induce antigen specific strong 
humoral and CTL response. The immunization with escheriosomes 
encapsulated cytosolic antigen imparted strong protection against challenge 
with virulent S. typhimurium infection in BALB/c mice as revealed by 
enhanced survival rate and reduced bacterial load in their vital organs. 
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Chemicals and Reagents 
All the reagents used in the study were of the highest purity available. 
Egg phosphatidylcholine (egg PC) was isolated and purified according to the 
published procedure as described previously in Chapter 1. Anti IgGl, anti 
IgG2a, anti CD80 and CD86 antibodies were procured from Pharmingen, 
San Diego, USA. Anti-IFN-y monoclonal antibody was from Genzyme, 
Boston, MA, USA. Rabbit anti mouse HRP conjugate, Nitrocellulose 
membrane (0.45|am) and Diaminobenzidine was from Sigma Chemical Co., 
USA. 
Animals 
Female BALB/c mice (8-10 weeks old), weighing 18 ± 2 gm. were 
used in the study. 
Bacterial cultures 
5. typhimurium (JNMC/S2) was kind gift from Dr. Indu Shukla 
(Department of Microbiology, Jawaharlal Nehru Medical College, Aligarh 
Muslim University, Aligarh). Bacteria were grown on NB- Agar plates 
overnight at 37°C. For harvesting the bacteria the single colony was 
streaked on fresh NB-Agar plate and incubated overnight at 37 °C. The loop 
full of bacteria from the plate was then taken and suspended in PBS and 
vortexed. The bacteria were enumerated by McFarland's standard taking the 
O.D.590 (0.1 O.D.590= IX 10* cfu/ml). 
E. coli lipids 
Lipids were isolated as by published method as described in chapter 
1.Briefly cell pellet was sonicated in methanol/chloroform and after 
filtration, filtrate was washed with l/S"* volume of normal saline and finally 
evaporated to thin dry film. 
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Preparation of vaccines 
Isolation of S.typhlmurium cytosolic antigen. S. typhimurium was 
cultured on LB broth at 37° C, overnight. Cells were harvested from mid log 
phase and washed in 50mM sodium phosphate buffer containing 0.15 M 
NaCl as a stabilizer. The bacterial cells were collected in lysis buffer 
containing 100 mM Tris-HCl (pH 8.0), lOOmM NaCI, (w/v), ImM EDTA 
and ImM PMSF. After brief sonication cocktail of protease inhibitor was 
also added to the cell suspension. It was further homogenized for 15 minutes 
with intermittent cooling followed by sonication for 15 min. at 4 °C using 
probe sonicator. The preparation was pelleted at 2000 g for 15 min. and the 
supernatant was collected. The protein was extensively dialyzed with three 
to four changes against PBS and stored in aliquots at -SO^C till further use. 
Preparation of DRVs. Dried reconstituted vesicles (DRVs) were prepared 
using published method (Kirby & Gregoriadis 1994) as described in 
materials and methods section of Chapter 1. Briefly, liposomes (egg 
PC/Chol & E.coli lipid) formed after hydrating and sonicating the thin lipid 
film were mixed with equal volume of cytosolic protein (10 mg/ml) solution. 
The mixture was flash frozen and thawed (three cycles) followed by 
lyophillization . The free-flowing, dried powder obtained was rehydrated 
with distilled water (120 |il) and finally reconstituted with PBS. The 
preparation was washed at least three times with PBS to remove the traces of 
the un-entrapped antigen. The protein entrapped in the liposomes was 
estimated by BCA method (Smith et. al. 1985). 
Immunization and infection of animals 
The animals were immunized subcutaneously with various forms of S. 
typhimurium cytosolic atigens viz. free antigen, antigen entrapped in egg-PC 
liposomes (PC-Ag), physical mixture of empty escheriosomes and antigen 
(sham EL+Ag) and antigen entrapped in escheriosomes (EL-Ag). Each group 
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consisted often animals. Initially in pilot experiments mice were immunized 
with varying concentration of free antigen (25 ^ig, 50 |ig, 100 |j.g ) to 
evaluate dose which gives maximum immune response. Finally, the mice 
were immunized with 100 |ig antigen (corresponds to -500 nmole of lipid) 
in 100 |A1 PBS on day 0 and subsequently boosted with 50 |a,g of antigen on 
day 21 and day 28. The mice were bled through retro-orbital puncture on 
seventh day after the last booster and subsequently challenged with 5x10^ 
cfu in 200|il PBS of virulent 5. typhimurium intra peritoneally and the 
establishment of infection was assessed from the survival rate and the CFU 
count in various vital organs of the animals. 
Determination of antigen specific antibodies by Western blot. 
The production of antigen-specific antibodies in sera of the animals 
immunized with various vaccines was determined by western blot analysis. 
Briefly, cytosolic antigens were separated by 10% SDS-PAGE and 
subsequently transferred to Nitrocellulose membrane in Trans Blot assembly 
(BioRad) containing transfer buffer (25mM Tris, 192mM Glycine and 20% 
Methanol) at 60V for 8 hrs. The membrane was blocked with 5% skimmed 
milk for 4hrs at 4°C and washed five times with PBS Tween. The membrane 
was cut into strips and incubated with (1:100) dilution of serum from 
various vaccinated groups in plastic bags on rocker for 2hrs at 4°C. The 
strips were washed with PBS Tween and incubated with 1:1000 dilution of 
HRP conjugated anti mice Ab for Ihr on rocker at 4°C. The strips were 
finally washed with PBST and developed with Diamino benzidine 
(10mg/6ml D.W.) in presence of 20^1 of 30% H2O2. 
Determination of antigen specific total IgG and isotypes by 
ELISA. 
The production of antigen specific total IgG and isotype antibodies 
were measured in the sera of the immunized mice bled after seven day of 
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the last booster. Briefly, ninety-six well microtitre plate was incubated 
overnight with 100 ^1 of cytosolic antigen (25 ng/ml) in carbonate-
bicarbonate buffer (0.05M, pH 9.6) at 4 °C. After usual washing and 
blocking steps the plate was finally incubated with log 2 dilutions of test 
and control sera at 37°C for 2h. After excessive washing of the plate, it was 
further incubated with 50 i^ l of biotinylated goat anti mouse IgGl and IgG2a 
antibodies. The plate was incubated at 37°C for Ih. After the usual washing 
steps, 50 |il of streptavidin-HRP were added to each well and the plate was 
incubated at 37 °C for Ih. The plate was washed again before adding 50 |al 
ABTS and was finally incubated at 37°C for 20 min. The reaction was 
terminated by the addition of 50 i^l of 7% H2SO4. The absorbance was read 
at 492 nm with a microtitre plate reader (Eurogenetics, Torino, Italy). 
Determination of IFN-y by ELISA 
IFN-y was estimated using appropriate purified and biotinylated 
antibody pairs for IFN-y (Genzyme) according to the manufacturers 
protocols. Briefly, 50^1 of the purified antimouse IFN-y MoAbs were 
adsorbed overnight on polystyrene microtitre plates at 4° C. Plates were 
washed five times with PBST and blocked with 5% skimmed milk. After 
usual steps of washing, the serum samples of control and immunized 
animals were added to the plate. After stipulated incubation time, the plate 
was thoroughly washed and incubated with biotinylated polyclonal goat 
antimouse IFN-y. Afterward, plate was washed three times with PBST. 
Later on 100 ^l of streptavidin-HRP was added to each well and plate was 
incubated for 20min at room temperature. Plate was again washed three 
times with PBST and finally developed with tetra methyl benzidine. The 
absorbance was read at 450 nm with a microtitre plate reader. Titration 
curves of recombinant IFN-y (Genzyme) were used as standard for 
calculating cytokine concentrations in the samples tested 
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Lymphoproliferation assay. 
Lymphocytes isolated from the spleens of the mice immunized sc 
with different vaccine preparations were cultured in flat-bottomed 96-well 
microtiter plates (Nunc), with 2 X lO' cells/well in 200^1 of RPMI 1640 
medium and 10% FCS. The cells were pulsed with different doses (0.001-
100 ng/ml) of free Ag or encapsulated in egg PC or E. coli lipid liposomes. 
Lymphocytes stimulated with the medium alone were used as a control. The 
cultures were incubated for 72 h at 37*'C/7%C02 .The cells were pulsed with 
1.0 )aCi [^H]-thymidine (Amersham Pharmacia Biotech) for 16 h before 
harvesting with an automatic cell harvester (Skatron, Tranby, Norway). The 
[^H]-thymidine incorporation was measured by a standard liquid scintillation 
counting method (LKB Wallac LS 1800; Beckman Instruments). The results 
are expressed as mean cpm of triplicate cultures. 
Cell mediated immune response against S. typhimurium cytosolic 
antigens. 
DTH response. The delayed type hypersensitivity (DTH) test was 
performed in the footpad of immunized mice by standard method (Collins & 
Mackaness 1968). Briefly, 50 |ag of salmonella cytosolic antigen in 50 |j.l of 
vehicle (normal saline, PC liposome or EC liposome) was injected in left 
hind footpad of mice. An equal volume of saline was injected into the 
opposite footpad. The thickness of footpad was measured by vernier calipers 
and DTH was expressed as the absolute increase in footpad thickness at 24 
hour post elicitation, the time at which maximum reaction was observed. 
Cell mediated immune response was assessed by measuring the increase in 
food pad thickness of immunized animals. 
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CDS* T lymphocyte response 
A. Cell preparation, 
(a) CD8^ T cells. 
Various groups of BALB/c mice were injected separately, through 
subcutaneous route, with a total three doses (day 0, 21, and 28) of free Ag, 
egg-PC-Ag or EL-Ag and also with sham EL-Ag. After seven days of last 
booster animals from each group where sacrificed and spleens were taken out 
aseptically. The cells were prepared as described elsewhere (Mitchell & 
Shiigi 1980). The cells obtained from different animals in a given group were 
pooled, purified and used in cyto-toxicity assay. The enriched population 
stained with anti-CD8 Ab, was >98% pure, as evaluated by FACScan. 
(b) Target cells 
BALB/c mice were injected with thioglycollate broth. On day 4, the 
macrophages were isolated from the PEC by adherence on Petri plates. The 
harvested cells (2xl0'cells/ml) were washed 3 times with HBSS and 
incubated at 37 *'C for 3-4 h with free Ag, egg PC-Ag, Sham EL-Ag or EL-
Ag. The cells were again washed 3x to remove free antigen. This was 
followed by incubation with ' 'Cr (100 |xCi/2xlO' cells) for 45-60 min at 37 
"C. The cells were finally washed with RPMI solution and were used as target 
cells. 
B. Cytotoxicity assay. 
The ^'Cr-labelled macrophages (5xlO^/well) were used as target cells. 
The antigen primed target cells were incubated with CD8"^  T cells (effector 
cells isolated from the spleen of the five mice were pooled, and used for 
assay) at an effector to target (E/T) ratios of 2.5:1-20:1. The cells were 
incubated at 37 °C for 6 h, after completion of incubation period, the cells 
were pelleted at 3000 x g (15 min, 5 °C) and the amount of ^'Cr released 
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was determined by measuring the radioactivity in the supernatant. The 
experiments were performed three times and the error bars represent 
standard deviation of the means from three different experiments. Total ^'Cr 
release was calculated by treating fixed number of the target cells with 
Triton X-100 (10% final concentration). The spontaneous release of ^'Cr in 
the supernatant was determined by incubating the labeled macrophages for 6 
h. Amount of auto-release was subtracted from the total release to determine 
the extent of macrophage lysis. In most of the experiments, the auto-release 
was less than 25%. The percent specific release was calculated as the (mean 
sample cpm-mean spontaneous cpm/mean maximum cpm-mean spontaneous 
cpm)x 100%. 
Expression of co-stimulatory molecules (CD80&CD86) on 
macrophages harvested from immunized and control animals 
The expression of CD80 and CD86 was detected on the surface of 
stimulated macrophages isolated from group of animals immunized with 
various types of vaccines following published protocol (Agrewala el. al. 
1998). The macrophages were isolated by adhering to plastic petri plates. 
The recovered adherent cells were consisted of >99% macrophages as 
adjudged by histochemistry and FACS analysis. The macrophages (1X10^ 
cells) were incubated with PC-Ag or EL-Ag (corresponding to 10|ag/ml 
antigen). The macrophages were first incubated with Fc block and 
subsequently, the cells were stained with FITC conjugated hamster anti-
mouse CD80 and CD86 (l^g/100nl) diluted in FACS buffer. The stained 
cells were acquired on FACScan (Beckton Dickinson, CA) and the 
population of macrophages were analysed on macrophage/monocyte zone 
using CELLQUEST software (Beckton Dickinson, CA). The exclusion of 
debris and lymphocytes from cell suspension by suitable gating allowed 
analysis of only those scattering events (i.e. cells) of size consistent with the 
macrophages. The analysis of mean fluorescence intensity (MFI) was 
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performed on histograms in which the abscissa and ordinate denote log FITC 
fluorescence and relative cell count respectively. 
Determination of bacterial load in various vital organs of 
immunized mice upon challenging with Salmonella pathogen 
Determination of bacterial load in liver and spleen of the immunized 
mice helped in the assessment of prophylactic efficacy of various vaccine 
preparations against Salmonella infection. The animals belonging to various 
immunization groups were sacrificed on day 7*'' post challenge with 
infection to know the effect of immunization on establishment of infection. 
The organs were macerated by frosted slides separately in autoclaved normal 
saline (5 ml) and an aliquot (200|il) of this suspension was plated on NB 
Agar plates after appropriate dilution. The colonies developed after 
incubation was counted and the bacterial load was calculated by multiplying 
with the respective dilution factor. The animals that survived the pathogen 
challenge were further assessed for the residual bacterial load in liver and 
spleen on day 15"* post infection. 
Statistical Analysis 
Statistical analysis was done by the Student's / test. P < 0.05 was 
considered statistically significant. 
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(1) Humoral immune response against S. typhimurium in mice 
immunized witii various vaccine preparation 
The female BALB/c mice upon immunization with various forms of S. 
typhimurium antigens generated antigen specific antibodies. The western 
blot analysis revealed enhanced antibody titer in animals immunized with 
EL-Ag whereas those immunized with PC-Ag and free antigen showed 
almost same level of antigen specific antibodies (Fig. 12). The antibody titer, 
which was determined on various time courses by ELISA, showed greater 
adjuvant potential of escheriosome-encapsulated antigen (EL-Ag). The 
antibody titer determined after first booster was found to be higher for 
escheriosomes (A492 0.53) as compared to PC liposomes (A492 0.34) and 
other groups at equal dilution of sera (1:500). There was significant 
enhancement in antibody titer in animals immunized with EL-Ag (A492 0.93) 
and PC-Ag (A492 0.72) at 1:500 dilutions of sera after second booster 
(Fig. 13). In order to evaluate the generation of antigen specific antibody 
isotypes to determine Thl/Th2 polarization we found elevated levels of both 
IgGl (A492 0.82) and IgG2a (A492 0.61) antibodies in escheriosome 
immunized animals. The animals immunized with PC-Ag have demonstrated 
relatively low level of both IgGl (A492 0.57) and IgG2a (A492 0.27) as 
compared to escheriosomes. (Fig. 14). 
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Figure 12: 
(a) SDS'PAGE profile of cytosolic proteins isolated from 
S.typhimurium. 
S.typhimurium were cultured in Nutrient broth and harvested from mid log 
phase and proteins were isolated as described in materials and methods. 
Each well was loaded with SO i^g of protein in sample buffer (25|il) and were 
run on 10% SDS-PAGE at 70 V for two hrs and stained with coomasic 
brilliant blue dye. 
(b) Induction of humoral immune response analysed by 
Western Blot in animals immunised with various 
preparation of vaccine. 
BALB/c mice after immunisation with various preparation of Salmonella 
vaccine were bled on seventh day of last booster and serum was separated. 
Protein samples were run on 10% SDS-PAGE and transferred to 
Nitrocellulose membrane at 60 V for 8hrs. The membrane was blocked with 
5% skimmed milk and incubated with serum (1:100) from various groups 
followed by incubation with HRP conjugated anti mice Ab and finally 
developed with DAB. Lane 1- control, Lane 2- Free-Ag, Lane 3- PC-Ag, 
Lane 4- EL-Ag. 
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Figure 13: Induction of humoral immune response 
measured by ELISA in animals immunised with 
various preparation of vaccine 
BALB/c mice after immunisation with various preparation of Salmonella 
vaccine were bled on seventh day of last booster to determine antigen 
specific total IgG in sera of various groups of animals by ELISA method. 
The data represents mean of five mice per group ± S.D and representative of 
three individual experiments. [ p value PC Vs EL-Ag < 0.01 (1** booster), 
< 0.005 (2"** booster)]. 
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Figure 14: Generation of antigen specific IgG isotypes in 
animals immunised witti various types of 
Salmonella vaccine. 
BALB/c mice after immunisation with various preparation of vaccine were 
bled on seventh day of last booster to determine antigen specific antibody 
isotypes (IgGl & IgG2a) in sera of various groups. Sera (1:500 dilution) 
obtained from the control and experimental animals were analysed for the 
presence of Ag-specific IgG-isotype by ELISA method as described in 
materials and methods. The levels of the two major isotypes of the IgGs 
were expressed as absorbance (A492) of the coloured complex developed in 
the immunosorbent assay. The values expressed are the mean of the 
absorbance of the sera of five different animals ± S.D. The control animals 
could not induce any detectable level of IgG-isotype ( p value Cont Vs EL-
Ag < 0.001, PC-Ag Vs El-Ag <0.01, FreeAg Vs EL-Ag <0.001). 
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(2) Potent lymphocyte proliferation induced by escheriosomes 
The lymphocytes obtained from the animals immunized with 
escheriosome encapsulated antigen generated significantly better 
proliferation compared with lymphocytes obtained from animals immunized 
with PC liposome encapsulated antigen. The proliferation response occurred 
in dose dependent manner. The maximum proliferation occurred when cells 
were stimulated with lO i^g antigen. The response was significantly higher 
for EL-Ag (-70000 cpm) as compared to PC-Ag (-30000 cpm). The groups 
immunized with free antigen or sham escheriosome could not generate 
significant level of T lymphocyte proliferation. The control animals that 
were immunized with phosphate buffer saline (PBS) failed to stimulate T 
lymphocyte (Fig. 15). 
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F i g u r e 1 5 : Antigen incorporated in Escheriosomes 
augmented tiie proliferation of antigen specific 
lymphocytes. 
Lymphocytes isolated from the spleens of the mice immunized 
subcutaneously with various vaccine preparations were cultured in flat-
bottomed 96-well microtiter plates. The cells were pulsed with different 
doses (0.001-100 ^g/ml) of free Ag or encapsulated in egg PC or 
escheriosomes as described in materials and methods. Lymphocytes 
stimulated with the medium alone were used as a control. After 72h, [-^ H]-
thymidine was added, and its incorporation was measured 16h later by liquid 
scintillation spectroscopy. The data represents mean cpm of three 
determinations ± S.D. The figure is representative of four different 
experiments with similar observations. 
Groups p value 
PC-Ag Vs EL-Ag <0.005 
Free Ag Vs EL-Ag <0.005 
104 
^AaAteit2: iyiemuA 
80x1 (P 
0.001 0.01 0.1 1.0 10.0 100.0 
Ag{ng/ml) 
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(3) Cell mediated immune response against S. typhimurium 
antigens 
DTH response. The development of cell-mediated immunity (CMI) is 
known to be important for the control of Salmonella infection. For example, 
DTH, which is an in vivo manifestation of CMI, has been shown to be 
parallel to the development of protective immunity in mice. As evident from 
Fig. 16, the animals that were immunized with escheriosome encapsulated 
antigen were able to induce strong DTH response (foot pad thickness, 
144mm) as compared to PC-Ag (58mm) while no DTH response was 
observed in control animals. Induction of CMI was further confirmed from 
the data of Fig. 17, which demonstrate that the animals immunized with 
escheriosomes have shown significant enhancement in the level of IFN-y (72 
pg/ml) as compared to PC-Ag immunized animals (44pg/ml) in their sera. 
CD8* T lymphocyte response 
Immunisation with cytosolic antigen entrapped in the escheriosomes 
(EL-Ag), but not other forms of Ag viz. free Ag or PC-Ag or antigen mixed 
with empty escheriosomes (sham EL+Ag), generated Salmonella antigen 
specific cytotoxic T cells. The lysis of antigen primed target cells was 
greatly affected by ratio of target versus effector cells. Around ~25% of 
target cell lysis occurred when effector to target ratio was 10:1, while it was 
-40% when ratio of effector cells was atleast 20 times higher to that of 
target cells. In contrast, less than 2% specific lysis occurred in PC liposomes 
encapsulated or free form of the antigen at same E:T ratio (Fig. 18). The 
physical mixture of the antigen with escheriosome failed to generate antigen 
specific CTLs that supports the notion that cytosolic delivery of the 
entrapped antigen could be executed with escheriosome encapsulated form 
of the antigen only. 
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F i g u r e 1 6 : DJH response in animals immunised witti 
various preparation of vaccine. 
The DTH response in animals vaccinated with various forms of 
antigen was determined by injecting 50 (ig of Salmonella cytosolic antigen 
in 50 nl of vehicle (normal saline, PC liposome or EC liposome) in left hind 
footpad of mice. An equal volume of saline was injected into the opposite 
footpad. The thickness of footpad was measured by Vernier calipers and 
DTH was expressed as the absolute increase in footpad thickness at 24 hour 
post immunization, the time at which maximum reaction was observed. 
Groups p value 
PC-AgVsEL-Ag <0.01 
Free Ag Vs EL-Ag <0.005 
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F i g u r e 1 7 : Enhanced secretion of IFN -y- in animals 
immunised witli escheriosomes. 
IFN- y in sera of various groups of animals immunised with various 
preparations of vaccine was determined by sandwich ELISA as described in 
materials and methods. The data is mean of five mice per group + S.D and 
representative of three different experiments (p value PC-Ag Vs EL-Ag 
<0.005, Free Ag Vs EL-Ag <0.001). 
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F igure 18 : induction of antigen specific CTL activity by 
immunisation with various preparation of 
vaccine. 
The BALB/c mice were immunised with ( • ) saline, ( • ) Free Ag, ( • ) sham 
EL, ( T ) sham escheriosomes mixed with Ag (EL + Ag), ( • ) Ag 
encapsulated in Egg PC liposomes (PC-Ag) and ( • ) Ag encapsulated in 
escheriosomes (EL-Ag), as described in materials and methods. The effector 
cells were isolated from spleen of five mice, belonging to various groups 
mentioned as above. The cells were pooled, purified and used for target cell 
lysis assay. The target cells were pulsed with saline, Free Ag , sham 
escheriosomes mixed with Ag (sham EL + Ag), Ag encapsulated in Egg PC 
liposomes (PC-Ag) and Ag encapsulated in escheriosomes (EL-Ag) 
respectively (30 ^g Ag/ 2 x 1 0 ^ cells), and labelled with ^'Cr. Lytic activity 
was measured by incubation of suitable effector cells with target cells 
(primed with matching formulation of Ag ). The results are represented as, 
percent specific lysis (^'Cr release) of the target cells. Each value represents 
the mean of three determinations ± S.D. Data are representative of five 
independent experiments performed with similar results. 
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(4) Escheriosomes enhances the surface expression of co-
stimulatory molecules (CD80 & CD86) 
The Flow cytometric analysis was conducted to evaluate the 
expression of CD80 & CD86 on the surface of macrophages isolated from 
group of animals vaccinated with PC-Ag and EL-Ag. The data of the present 
study clearly reveal that macrophages isolated from animals vaccinated with 
EL-Ag showed significantly higher level of expression of both CD80 [MFI 
26.8] & CD86 [MFI 48.3] on their surface. In contrast, macrophages isolated 
from animals vaccinated with PC-Ag expressed relatively less costimulatory 
signals [MFI CD80: 18.66 and CD86: 22.7] (Fig. 19). 
(5) Role of escheriosomes in protection of BALB/c mice against 
challenge with virulent S typhimurium 
Vaccine potential of escheriosome encapsulating S.typhimurium 
antigens against experimental murine salmonellosis was assessed on the 
basis of survival rate of the immunized animals. The survival data on day 
25*'' post infection showed 80% survival of the animals, which were 
immunised with escheriosome encapsulated antigen. There was only 37.5 % 
survival in animals immunized with Egg PC liposomes, while it was 27.5% 
in free Ag and 27.5% in EL+Ag immunized group. None of the animals 
survived in the control group (Fig 20). 
The efficacy of escheriosomes based vaccines to impart protection 
against salmonellosis was further confirmed by determining residual 
bacterial load in various vital organs. The animals were sacrificed on day 
seventh and day fifteenth post infection to determine bacterial load in two 
different organs viz. spleen and liver. The bacterial load data demonstrated 
that the animals vaccinated with antigen entrapped in escheriosome have 
significantly less bacterial burden in spleen (581.66 cfu) and liver (368 cfu) 
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as compared to spleen (1454.66 cfu) and liver (653 cfu) of PC-Ag and spleen 
(6895.33 cfu) and liver (1332.33 cfu) of Free-Ag group. The control group 
was found to be highly infected with spleen (13347.33cfu) and liver 
(6350.66 cfu) on day seventh post infection **/7<0.001 (Fig 21). Further 
animals surviving after day 15 were virtually free of any bacterial burden in 
both spleen (21.12 cfu) and liver (54.11 cfu) of EL-Ag immunised group. 
However significant numbers of bacteria were recovered from both liver 
(392.33 cfu) and spleen (799.88 cfu) of PC-Ag group and liver (945.66 cfu) 
and spleen (3756.22 cfu) of Free Ag group. None of the animals survived in 
control groups on day 15"' post infection (Fig 22). 
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Figure 19: Status of expression of costimulatory molecules 
(CD80 and CD86) on macrophages isolated from 
animals vaccinated with PC-Ag and EL-Ag. 
Status of expression of CD80 & CD86 on macrophages of animals 
immunised vfcith PC-Ag and EL-Ag was evaluated by Flow Cytometry as 
described in materials and methods. Shaded portion in the histogram depicts 
isotype control and unshaded portion depicts the cells expressing 
costimulator}. signals (p value < 0.01). 
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Figure 20: Prophylactic potential of escheriosomes in 
terms of survival rate of animals that were 
challenged with S. typhimurium infection after 
immunization with various preparation of 
vaccina. 
The animals immunised with various preparation of vaccine were challenged 
after seven days of last booster with SxlQ-* cfu in 200|^ 1 PBS of virulent S. 
typhimurium intra peritoneiilly. The animals were monitored for survival till 
day 30'*' post challenge. Iwich group consisted of 10 animals. Data is 
representative of five diffcrcnl experiments. 
Groups P value 
PC-Ag Vs EL-Ag <0.05 
Free Ag Vs EL-Ag <0.05 
Control Vs EL-Ag <0.001 
Control Vs PC-Ag <0.05 
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Effect of immunization on establishment of 
infection in animals immunised with various 
forms of vaccine 
The bacterial burden in various vital organs of the immunised animals was 
determined on day 7' post challenge with Salmonella infection. The animals 
were sacrificed by cervical dislocation and liver and spleen were taken out 
aseptically. The organ was macerated in normal saline and plated on NB 
Agar plates after appropriate dilutions as described in materials and 
methods. The data is mean ± S.D of three mice per group and representative 
of three different experiments.( p Value Cont Vs EL-Ag < 0.001, PC-Ag Vs 
EL-Ag 0.02, FreeAg Vs EL-Ag <0.001). 
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Figure 22: Prophylactic efficacy of esclieriosomes evaluated 
on day 15*'^ post infection 
The bacterial burden in liver and spleen of the immunised animals was 
determined on day 15"" post challenge with Salmonella infection to evaluate 
prophylactic efficacy of escheriosomes as described in materials and 
methods. The animals immunised with PBS and empty liposomes did not 
survive till day 15'^ post infection. The data is mean ± S.D of three mice per 
group and representative of three different experiments ( p Value Cont Vs 
EL-Ag < 0.001, PC-Ag Vs EL-Ag 0.02, FreeAg Vs EL-Ag <0.001). 
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Murine salmonellosis has been used for decades to model the 
pathogenesis and immunology of human typhoid fever because Salmonella 
typhimurium develops systemic infection in mice reminiscent of human 
typhoid (Bakken & Vogelsang 1950, Collins 1972). It is facultative 
intracellular pathogen, which invades the gastrointestinal mucosa thorough 
the specialized M cells in the payers patches, then spread into mesenteric 
lymph node where they are thought to reside and multiply within the 
macrophages (Sutter 1956, Nalue et. al. 1992). From the lymph node 
bacteria disseminate via the thoracic duct into the blood stream and are 
removed by the macrophage of the reticulo-endothelial system (RES), 
mainly in the spleen, liver and bone marrow. It is believed that salmonella 
multiply in the RES macrophage and are seeded back into the blood stream 
possibly through apoptosis of these cells; until a T cell mediated immune 
response begins to control infection through up regulation of RES 
macrophages. The relative importance of activation of both T and B cells in 
unison for long term protection against virulent Salmonella infection has 
been intensively investigated, ironically still remained much debated 
(Mastreoni et. al. 1994). Some groups have demonstrated the role of B cell 
dependent humoral immunity in vaccine induced protection, while others 
have advocated the role of CD4^ and CD8^ t cells along with TNF-a and 
IFN-y for full-acquired resistance to Salmonella spp. This is further 
supported by the fact that animals with defective T- cell activity readily 
succumbed to infection as compared to their normal counterparts (Eisenstein 
et. al. 1984,Collins I974,0rnellas et. al. 1970). It can be inferred that it is 
the cell-mediated branch of the immune system that plays an important role 
in protection against intracellular pathogens (Muotiala & Makela 1990, 
Nauciel & Espinasse 1992). The ability of CD8^ cytotoxic T lymphocytes 
(CTLs) to eliminate host cells infected with intracellular bacteria, in a 
manner similar to virus and other intracellular parasites, is now considered 
to be one of the major immunological effector mechanisms in protection 
119 
^AaJUeit2: ^taouMton 
against such infection. Since S. typhimurium is intracellular pathogen we 
speculated that CTL by destroying bacilli harbouring host cell, might play a 
crucial role in limiting progression of infection. It seems development of 
vaccine capable of generating significant level of cell-mediated immune 
response would be of considerable value. The present study is an attempt to 
develop candidate vaccine against typhoid fever. The idea of using 
escheriosomes for vaccination was inspired from our earlier studies showing 
fusogenic potential of E.coli lipid (Ahmad et. al. 2001). We exploited these 
liposomes to direct exogenous Salmonella antigens for both MHC-I and 
MHC-II processing and presentation pathways that eventually impart 
protective immunity against pathogen. The first part of the study was 
conducted to examine whether use of escheriosomes as delivery vehicle for 
Salmonella antigen will generate effective immune response against S. 
typhimurium. The studies revealed that — 
a) escheriosome antigen combination strongly activate humoral immune 
system of the host(Fig 12 &13), 
b) beside IgGl, immunization elicited the production of IgG2a type 
antibodies(Fig 14), 
c) significant proliferation of antigen specific lymphocytes in 
immunized animals (Fig 15), 
d) elicitation of strong CTL response against salmonella antigen (Fig 16 
«&18), 
e) production of type 1 cytokine IFN- y (Fig 17), 
f) significant upregulation of costimulatory molecules (CD80/CD86) in 
splenocytes (Fig 19), 
The above immunological responses elicited in the immunized 
animals can be explained on the premise that unlike conventional liposomes, 
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escheriosomes readily fuses with the target cell to deliver the antigen into 
cytosol of APC to be expressed by MHC-I molecule leading to activation of 
cytotoxic T lymphocyte (CTLs). Beside the fraction of antigen delivered into 
endocytic pathway may activate MHC class II restricted antigen processing 
pathway that will help in activation of humoral immune response. 
Immunization with escheriosome-encapsulated antigen generates high 
antibody titer as revealed by both western blot analysis and ELISA (Fig 12& 
Fig 13). Moreover it also released enhanced level of both IgGl and IgG2a 
antibodies as compared to egg PC liposome encapsulated or free form of 
antigen (Fig 14), The lymphocyte proliferation was maximum in the animals 
immunised with EL-Ag (Fig 15). Moreover, significant level of CTL 
response was observed in animals vaccinated with escheriosomes. For 
example, effector cells obtained from animals immunized with 
escheriosomes were able to cause 40% lysis of target cells whereas less than 
2% lysis was observed in case of eggPC liposome encapsulated or free form 
of antigen (Fig 18). Similarly strong DTH response and enhanced secretion 
of IFN- Y in animals vaccinated with escheriosomes suggest that there is 
elicitation of considerable degree of cell mediated immune response (Fig 16 
& Fig 17). In contrast, no significant cell mediated immune response were 
elicited in control groups including the one that was immunized with egg PC 
liposome encapsulated antigen. The FACS results showed enhanced 
expression of CD80 and CD86 on the surface of splenocytes isolated from 
escheriosomes vaccinated animals (Fig 19). It has been demonstrated that 
these costimulatory molecules are very important in stimulating the optimum 
activation of T-cells (Agrewala et. al. 1998, Susvas et. a/. 2002). Inhibition 
of their expression might lead to anergy rather than activation of T cells. As 
successful delivery of Ag to APC will not necessarily ensue in induction of 
immune response since presence of antigen alone constitutes signal 1. To 
successfully induce an immune response, it is necessary that signal 2 should 
also be present which is triggered by co stimulatory molecules. Thus 
121 
^nc^/etc 2: ^tMxudon 
induction of considerable degree of CTL response in conjunction witii 
enhanced expression of co stimulatory molecules on the surface of APC 
suggest that escheriosomes not only deliver antigen to cytosol of APC for its 
presentation through MHC I molecule but also enhances expression of 
accessory molecules inducing co stimulatory signals to T cells leading to 
optimum elicitation of cell mediated immune response in vivo as well. 
The higher efficacy of escheriosomes as vaccine adjuvant may be 
attributed to simultaneous activation of both humoral and cell mediated 
immune responses. This is in accordance with the report of Krishnan et. ai, 
according to which fusogenic liposomes (archeosome) based antigen 
delivery system can induce both the arms of immune system simultaneously 
(Krishnan et al, 2000). Recently, Gerosa et. al. have demonstrated that genes 
for both typel and type2 class of cytokines are independently regulated and 
that any combination of them can be observed without a clear distinction 
along the Thl or Th2 phenotype (Gerosa et. a/. 1996). 
After establishing immune potential of escheriosomes against 
cytosolic antigen of S. typhimurium, in the next set of experiment we 
evaluated their ability as suitable vaccine candidates in imparting protection 
against S. typhimurium in BALB/c mice. The following major findings have 
emerged from the study: 
(a) escheriosomes were able to impart better protection in terms of 
survival rate as compared to conventional egg PC liposomes 
against 5. typhimurium infection in BALB/c mice (Fig 20), 
(b) escheriosome based vaccine successfully eradicated bacterial 
burden from animals survived after challenge with infection 
(Fig 21 &22), 
(c) escheriosome based vaccine can suppress virulence of S. 
typhimurium. 
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The protection studies demonstrate better survival rate in animals, 
which were immunized with escheriosomes encapsulated antigen, almost 
80% of animals survived on day 25^'' post infection in comparison to 
animals immunized with egg PC/ Choi liposomised antigen in which 
survival rate was only 37.5%. (Fig.20). Egg PC liposomes generally lead to 
the activation of humoral immune response, and thus able to eliminate only 
limited number of microbes as their intracellular residence may help to 
escape the antibody mediated killing, which ultimately resulted in 
recurrence of the infection and subsequent death of the animal. The 
effectiveness of escheriosomes may be explained on the premise that these 
liposomes apart from generating humoral response were also able to mount 
strong CTL immune response, and hence successfully eliminate the 
pathogen from host by activating both humoral and cell-mediated 
mechanisms. The escheriosome-mediated protection against S. typhimurium 
was further confirmed by remarkable decrease of bacterial load in different 
vital organs of animals immunized with escheriosome-encapsulated 
antigens. There was significant reduction in bacterial load in liver and 
spleen of animals vaccinated with EL-Ag on day seventh post infection 
(Fig 21). In fact, the animals vaccinated with EL-Ag were found to be 
virtually free of any bacterial load on day IS*** post infection (Fig.22) 
Several vaccination strategies available today are able to induce 
humoral immunity mainly and to lesser degree cell mediated immune 
response. So far only two vaccines have been developed during last fifteen 
years and are licenced for use against typhoid fever. The first one is a 
parenteral capsular polysaccharide vaccine based on S. enterica var. typhi 
Vi antigen. This vaccine has been shown to stimulate protective immune 
responses against typhoid fever and is generally considered efficacious, 
however it suffers from limitations that its administration is accompanied 
by localized pain at the injection site and require frequent boosters (Hassel 
et. al. 1999). Second licensed typhoid vaccine currently available is live 
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attenuated oral vaccine containing S enterica var Typhi strain Ty21a. 
Although this vaccine is safe and effective but is modestly immunogenic 
and requires three to four initial doses (Wahdan et. al. 1982, Levine et. al. 
1999). Moreover its immunogenicity decreases with simultaneous 
administration of antimalarial drugs (Kollatritch et. al. 1997). Thus with the 
limitations associated with both of these vaccines there is urgent need for 
development of more efficacious and better-defined vaccines. 
Finally we conclude that escheriosome based vaccines offer effective 
strategy in imparting protection against challenge with virulent S. 
typhimurium infection and may prove to be equally effective against other 
infectious diseases also. 
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